<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">105087</article-id><article-id pub-id-type="doi">10.7554/eLife.105087</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.105087.3</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Neuroscience</subject></subj-group></article-categories><title-group><article-title>Interleukin-4 induces CD11c<sup>+</sup> microglia leading to amelioration of neuropathic pain in mice</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kohno</surname><given-names>Keita</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-5038-5680</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Shirasaka</surname><given-names>Ryoji</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Hirose</surname><given-names>Keita</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Masuda</surname><given-names>Takahiro</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-3687-452X</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund9"/><xref ref-type="other" rid="fund10"/><xref ref-type="other" rid="fund11"/><xref ref-type="other" rid="fund12"/><xref ref-type="other" rid="fund13"/><xref ref-type="other" rid="fund15"/><xref ref-type="other" rid="fund16"/><xref ref-type="other" rid="fund18"/><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Tsuda</surname><given-names>Makoto</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0585-9570</contrib-id><email>tsuda@phar.kyushu-u.ac.jp</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund19"/><xref ref-type="other" rid="fund20"/><xref ref-type="other" rid="fund21"/><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00p4k0j84</institution-id><institution>Department of Molecular and System Pharmacology, Graduate School of Pharmaceutical Sciences, Kyushu University</institution></institution-wrap><addr-line><named-content content-type="city">Fukuoka</named-content></addr-line><country>Japan</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00p4k0j84</institution-id><institution>Division of Molecular Neuroimmunology, Medical Institute of Bioregulation, Kyushu University</institution></institution-wrap><addr-line><named-content content-type="city">Fukuoka</named-content></addr-line><country>Japan</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00p4k0j84</institution-id><institution>Kyushu University Institute for Advanced Study</institution></institution-wrap><addr-line><named-content content-type="city">Fukuoka</named-content></addr-line><country>Japan</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Owoyele</surname><given-names>Bamidele</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/032kdwk38</institution-id><institution>University of Ilorin</institution></institution-wrap><country>Nigeria</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Taffe</surname><given-names>Michael A</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0168r3w48</institution-id><institution>University of California, San Diego</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>01</day><month>08</month><year>2025</year></pub-date><volume>14</volume><elocation-id>RP105087</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2024-12-03"><day>03</day><month>12</month><year>2024</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2024-12-09"><day>09</day><month>12</month><year>2024</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2024.12.05.627015"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2025-02-07"><day>07</day><month>02</month><year>2025</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.105087.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2025-07-17"><day>17</day><month>07</month><year>2025</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.105087.2"/></event></pub-history><permissions><copyright-statement>Â© 2025, Kohno et al</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Kohno et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-105087-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-105087-figures-v1.pdf"/><abstract><p>Neuropathic pain, a debilitating chronic pain condition, is a major clinical challenge. The pleiotropic cytokine interleukin-4 (IL-4) has been shown to suppress neuropathic pain in rodent models, but its underlying mechanism remains unclear. Here, we show that intrathecal administration of IL-4 to mice with spinal nerve transection (SpNT) increased the number of CD11c<sup>+</sup> microglia (a microglia subset important for pain remission) in the spinal dorsal horn (SDH) and that this effect of IL-4 was essential for its ameliorating effect on SpNT-induced pain hypersensitivity. Furthermore, in mice with spared nerve injury (SNI), another model in which pain remission does not occur, the emergence of CD11c<sup>+</sup> SDH microglia was curtailed, but intrathecal IL-4 increased their emergence and ameliorated pain hypersensitivity in a CD11c<sup>+</sup> microglia-dependent manner. Our study reveals a mechanism by which intrathecal IL-4 ameliorates pain hypersensitivity after nerve injury and provides evidence that IL-4 increases CD11c<sup>+</sup> microglia with a function that ameliorates neuropathic pain.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>neuropathic pain</kwd><kwd>microglia</kwd><kwd>spinal cord</kwd><kwd>interleukin4</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001691</institution-id><institution>Japan Society for the Promotion of Science</institution></institution-wrap></funding-source><award-id>JP23K19403</award-id><principal-award-recipient><name><surname>Kohno</surname><given-names>Keita</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001691</institution-id><institution>Japan Society for the Promotion of Science</institution></institution-wrap></funding-source><award-id>JP24K18621</award-id><principal-award-recipient><name><surname>Kohno</surname><given-names>Keita</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002241</institution-id><institution>Japan Science and Technology Agency</institution></institution-wrap></funding-source><award-id award-id-type="doi">10.52926/JPMJAX232B</award-id><principal-award-recipient><name><surname>Kohno</surname><given-names>Keita</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100009619</institution-id><institution>Japan Agency for Medical Research and Development</institution></institution-wrap></funding-source><award-id>JP20gm6310016</award-id><principal-award-recipient><name><surname>Masuda</surname><given-names>Takahiro</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100009619</institution-id><institution>Japan Agency for Medical Research and Development</institution></institution-wrap></funding-source><award-id>JP21wm0425001</award-id><principal-award-recipient><name><surname>Masuda</surname><given-names>Takahiro</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100009619</institution-id><institution>Japan Agency for Medical Research and Development</institution></institution-wrap></funding-source><award-id>JP23gm1910004</award-id><principal-award-recipient><name><surname>Masuda</surname><given-names>Takahiro</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100009619</institution-id><institution>Japan Agency for Medical Research and Development</institution></institution-wrap></funding-source><award-id>JP23jf0126004</award-id><principal-award-recipient><name><surname>Masuda</surname><given-names>Takahiro</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100009619</institution-id><institution>Japan Agency for Medical Research and Development</institution></institution-wrap></funding-source><award-id>24zf0127012</award-id><principal-award-recipient><name><surname>Masuda</surname><given-names>Takahiro</given-names></name></principal-award-recipient></award-group><award-group id="fund9"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001691</institution-id><institution>Japan Society for the Promotion of Science</institution></institution-wrap></funding-source><award-id>JP21H02752</award-id><principal-award-recipient><name><surname>Masuda</surname><given-names>Takahiro</given-names></name></principal-award-recipient></award-group><award-group id="fund10"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001691</institution-id><institution>Japan Society for the Promotion of Science</institution></institution-wrap></funding-source><award-id>JP22H05062</award-id><principal-award-recipient><name><surname>Masuda</surname><given-names>Takahiro</given-names></name></principal-award-recipient></award-group><award-group id="fund11"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001691</institution-id><institution>Japan Society for the Promotion of Science</institution></institution-wrap></funding-source><award-id>JP25H01009</award-id><principal-award-recipient><name><surname>Masuda</surname><given-names>Takahiro</given-names></name></principal-award-recipient></award-group><award-group id="fund12"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100005927</institution-id><institution>Daiichi Sankyo Foundation of Life Science</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Masuda</surname><given-names>Takahiro</given-names></name></principal-award-recipient></award-group><award-group id="fund13"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100005865</institution-id><institution>Mochida Memorial Foundation for Medical and Pharmaceutical Research</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Masuda</surname><given-names>Takahiro</given-names></name></principal-award-recipient></award-group><award-group id="fund14"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100007263</institution-id><institution>Astellas Foundation for Research on Metabolic Disorders</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Masuda</surname><given-names>Takahiro</given-names></name></principal-award-recipient></award-group><award-group id="fund15"><funding-source><institution-wrap><institution>Ono Pharmaceutical Foundation for Oncology, Immunology and Neurology</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Masuda</surname><given-names>Takahiro</given-names></name></principal-award-recipient></award-group><award-group id="fund16"><funding-source><institution-wrap><institution>The Nakajima Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Masuda</surname><given-names>Takahiro</given-names></name></principal-award-recipient></award-group><award-group id="fund17"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100008732</institution-id><institution>Uehara Memorial Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Masuda</surname><given-names>Takahiro</given-names></name></principal-award-recipient></award-group><award-group id="fund18"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100007449</institution-id><institution>Takeda Science Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Masuda</surname><given-names>Takahiro</given-names></name></principal-award-recipient></award-group><award-group id="fund19"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001691</institution-id><institution>Japan Society for the Promotion of Science</institution></institution-wrap></funding-source><award-id>JP19H05658</award-id><principal-award-recipient><name><surname>Tsuda</surname><given-names>Makoto</given-names></name></principal-award-recipient></award-group><award-group id="fund20"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001691</institution-id><institution>Japan Society for the Promotion of Science</institution></institution-wrap></funding-source><award-id>JP20H05900</award-id><principal-award-recipient><name><surname>Tsuda</surname><given-names>Makoto</given-names></name></principal-award-recipient></award-group><award-group id="fund21"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001691</institution-id><institution>Japan Society for the Promotion of Science</institution></institution-wrap></funding-source><award-id>JP24H00067</award-id><principal-award-recipient><name><surname>Tsuda</surname><given-names>Makoto</given-names></name></principal-award-recipient></award-group><award-group id="fund22"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100009619</institution-id><institution>Japan Agency for Medical Research and Development</institution></institution-wrap></funding-source><award-id>25gm1510013h</award-id><principal-award-recipient><name><surname>Tsuda</surname><given-names>Makoto</given-names></name></principal-award-recipient></award-group><award-group id="fund23"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100009619</institution-id><institution>Japan Agency for Medical Research and Development</institution></institution-wrap></funding-source><award-id>JP25ama121031</award-id><principal-award-recipient><name><surname>Tsuda</surname><given-names>Makoto</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Increasing CD11c<sup>+</sup> microglial subsets in the spinal dorsal horn by intrathecal treatment of interleukin-4 alleviate pain hypersensitivity caused by nerve injury.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Neuropathic pain is a debilitating chronic pain condition that results from injury or disease of the somatosensory system. Since chronic pain is refractory to currently available treatments, the development of effective treatments is a major clinical challenge (<xref ref-type="bibr" rid="bib8">Colloca et al., 2017</xref>; <xref ref-type="bibr" rid="bib13">Finnerup et al., 2021</xref>). Accumulating evidence from studies using models of neuropathic pain indicates that peripheral nerve injury causes various inflammatory responses in the nervous system that critically contribute to the development of neuropathic pain (<xref ref-type="bibr" rid="bib20">Ji et al., 2016</xref>; <xref ref-type="bibr" rid="bib18">Inoue and Tsuda, 2018</xref>). Especially, pro-inflammatory cytokines [e.g. interleukin-1Î² (IL-1Î²), IL-6 and tumor necrosis factor Î± (TNFÎ±)] produced by various non-neuronal cells such as macrophages at injured nerves and dorsal root ganglion (DRG), and glial cells (mainly microglia and astrocytes) in the spinal dorsal horn (SDH) modulate function of primary afferent sensory neurons and SDH neurons, leading to an increase in the excitability of pain signaling neural pathway (<xref ref-type="bibr" rid="bib20">Ji et al., 2016</xref>; <xref ref-type="bibr" rid="bib18">Inoue and Tsuda, 2018</xref>; <xref ref-type="bibr" rid="bib21">Ji et al., 2019</xref>; <xref ref-type="bibr" rid="bib14">Grace et al., 2014</xref>). Along with these findings, much attention has been paid to the pain-relieving role of anti-inflammatory cytokines (<xref ref-type="bibr" rid="bib47">Vanderwall and Milligan, 2019</xref>). These include IL-10, the role of which in chronic pain has been extensively studied (<xref ref-type="bibr" rid="bib47">Vanderwall and Milligan, 2019</xref>). Another anti-inflammatory cytokine with pain-relieving effects in diverse models, including neuropathic pain, is IL-4. Intraplantar or systemic administration of IL-4 has been shown to attenuate pain behavioral responses to bradykinin (<xref ref-type="bibr" rid="bib10">Cunha et al., 1999</xref>), carrageenin (<xref ref-type="bibr" rid="bib10">Cunha et al., 1999</xref>), TNFÎ± (<xref ref-type="bibr" rid="bib10">Cunha et al., 1999</xref>), zymosan (<xref ref-type="bibr" rid="bib46">Vale et al., 2003</xref>), and acetic acid (<xref ref-type="bibr" rid="bib46">Vale et al., 2003</xref>) in normal animals. In models of neuropathic pain, single or repeated administration of IL-4 around the injured sciatic nerve reduced behavioral pain hypersensitivity (<xref ref-type="bibr" rid="bib4">Celik et al., 2020</xref>; <xref ref-type="bibr" rid="bib24">Kiguchi et al., 2015</xref>; <xref ref-type="bibr" rid="bib28">Labuz et al., 2021</xref>). These effects of IL-4 have been proposed to involve a decrease in the production of inflammatory mediators (<xref ref-type="bibr" rid="bib24">Kiguchi et al., 2015</xref>), polarization of macrophages toward an anti-inflammatory phenotype at injured nerves (<xref ref-type="bibr" rid="bib4">Celik et al., 2020</xref>; <xref ref-type="bibr" rid="bib24">Kiguchi et al., 2015</xref>), increases in the production and release of IL-10 (<xref ref-type="bibr" rid="bib24">Kiguchi et al., 2015</xref>) and opioid peptides (<xref ref-type="bibr" rid="bib4">Celik et al., 2020</xref>; <xref ref-type="bibr" rid="bib28">Labuz et al., 2021</xref>) from macrophages, and inhibition of the increased action potentials of DRG neurons (<xref ref-type="bibr" rid="bib35">Nie et al., 2018</xref>). In addition to the diverse actions of IL-4 at the peripheral level, the central nervous system, including the spinal cord, is recognized as an important locus of action of IL-4 in pain control. Intrathecal administration of IL-4 prevents the development of mechanical pain hypersensitivity in several neuropathic pain models (<xref ref-type="bibr" rid="bib35">Nie et al., 2018</xref>; <xref ref-type="bibr" rid="bib37">Okutani et al., 2018</xref>). The target cells for the action of IL-4 intrathecally administered could be microglia since, within the SDH of nerve-injured rats, IL-4 receptor Î± chain (IL-4RÎ±) is predominantly expressed in microglia (<xref ref-type="bibr" rid="bib37">Okutani et al., 2018</xref>). In line with this, intrathecal IL-4 activates signal transducer and activator of transcription 6 (STAT6; an intracellular signal transduction molecule downstream of IL-4RÎ±) in SDH microglia (<xref ref-type="bibr" rid="bib37">Okutani et al., 2018</xref>). Intrathecal IL-4 or other manipulation to increase spinal IL-4 during the early phase after nerve injury suppresses cellular indexes for reactive microglia (<xref ref-type="bibr" rid="bib37">Okutani et al., 2018</xref>), IL-1Î² and Prostaglandin E2 release, and microglial p38 phosphorylation (<xref ref-type="bibr" rid="bib15">Hao et al., 2006</xref>), all of which are required to develop pain hypersensitivity (<xref ref-type="bibr" rid="bib18">Inoue and Tsuda, 2018</xref>). In addition to the effect of IL-4 on pain development, it is noteworthy that intrathecal administration of IL-4 during the late phase (e.g. 2 weeks or later after nerve injury) leads to recovery from a behavioral pain-hypersensitive state that develops following nerve injury (<xref ref-type="bibr" rid="bib37">Okutani et al., 2018</xref>). Despite the remarkable therapeutic potential of spinal IL-4 for ameliorating established neuropathic pain, little is known about its mechanism of action. Given that the reactive states of microglia occur early after nerve injury (e.g. cell number and expression of proinflammatory genes) and subside in the late phase (<xref ref-type="bibr" rid="bib18">Inoue and Tsuda, 2018</xref>; <xref ref-type="bibr" rid="bib25">Kohno et al., 2018</xref>; <xref ref-type="bibr" rid="bib43">Tansley et al., 2022</xref>), it is possible that the pain-resolving effect of IL-4 involves a mechanism other than the previously reported suppression of inflammatory responses in activated microglia.</p><p>In this study, using two different models of neuropathic pain, we demonstrated that intrathecally administered IL-4 during the late phase changes microglia to a CD11c<sup>+</sup> state, which has recently been shown to be necessary for the spontaneous remission of behavioral hypersensitivity associated with neuropathic pain (<xref ref-type="bibr" rid="bib26">Kohno et al., 2022</xref>), and, importantly, that this is required for the pain-relieving effect of intrathecal IL-4. Consequently, our findings uncover a mechanism for the ameliorating effect of spinal IL-4 on already-developed neuropathic pain and provide evidence at a preclinical level that IL-4 could induce the emergence of CD11c<sup>+</sup> microglia with a function that resolves neuropathic pain.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Intrathecal treatment of IL-4 increases CD11c<sup>+</sup> microglia in the SDH and alleviates pain hypersensitivity after SpNT</title><p>To examine the effect of IL-4 on the behavioral remission of neuropathic pain, we used mice with spinal nerve transection (SpNT; a model of neuropathic pain <xref ref-type="bibr" rid="bib16">Ho Kim and Mo Chung, 1992</xref>; <xref ref-type="bibr" rid="bib40">Rigaud et al., 2008</xref>) and repeated the administration of IL-4 to their intrathecal spaces from day 14 post-SpNT, when the paw withdrawal threshold (PWT) decreased (indicating that mechanical pain hypersensitivity had been developed) (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). Intrathecal treatment with IL-4 increased the PWT in the hindpaw ipsilateral (but not contralateral) to the SpNT (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). Notably, this behavioral remission of neuropathic mechanical hypersensitivity persisted for at least 5 days after the last intrathecal injection of IL-4. Because we previously showed that CD11c<sup>+</sup> microglia emerging in the SDH after SpNT are necessary for the spontaneous remission of pain behavior that gradually occurs around 3 weeks after nerve injury (<xref ref-type="bibr" rid="bib26">Kohno et al., 2022</xref>), we explored the mechanism of action of spinal IL-4 with a focus on CD11c<sup>+</sup> microglia in the SDH. In <italic>Itgax-Venus</italic> mice, in which CD11c<sup>+</sup> cells are visualized using the fluorescent protein Venus (<xref ref-type="bibr" rid="bib26">Kohno et al., 2022</xref>; <xref ref-type="bibr" rid="bib29">Lindquist et al., 2004</xref>), SpNT increased the number of Venus<sup>+</sup> (CD11c<sup>+</sup>) cells in the SDH ipsilateral to the injury (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). Consistent with our previous data (<xref ref-type="bibr" rid="bib26">Kohno et al., 2022</xref>), almost all CD11c<sup>+</sup> cells were immunohistochemically positive for ionized calcium-binding adapter molecule 1 (IBA1) and the purinergic P2Y12 receptor (P2Y12R; <xref ref-type="fig" rid="fig1">Figure 1B and C</xref>), which are markers for myeloid cells and microglia, respectively (<xref ref-type="bibr" rid="bib3">Butovsky et al., 2014</xref>; <xref ref-type="bibr" rid="bib19">Ito et al., 1998</xref>). We found that intrathecal administration of IL-4 to SpNT mice enhanced the increase in CD11c<sup>+</sup> cells in the SDH (<xref ref-type="fig" rid="fig1">Figure 1BâD</xref>). These cells also expressed both IBA1 and P2Y12R (<xref ref-type="fig" rid="fig1">Figure 1B and C</xref>), indicating that CD11c<sup>+</sup> cells increased by intrathecal IL-4 were microglia. Quantitative flow cytometry analysis revealed a significant increase in CD11c<sup>+</sup> microglia in the SDH of IL-4-treated SpNT mice (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). In contrast, IL-4 did not significantly change the total number of microglia in the SDH (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). In addition, intrathecal IL-4 did not induce infiltration of CD169<sup>+</sup> monocytes/macrophages into the SDH (<xref ref-type="fig" rid="fig1s1">Figure 1âfigure supplement 1A</xref>). These findings suggest that CD11c<sup>+</sup> microglia may be involved in the mechanism by which intrathecal treatment with IL-4 attenuates pain hypersensitivity.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>IL-4 increases CD11c<sup>+</sup> microglia in the SDH and ameliorates pain hypersensitivity in the SpNT mice.</title><p>(<bold>A</bold>) Paw withdrawal threshold (PWT) of <italic>Itgax-Venus</italic> mice before (Pre) and after SpNT (n=7â8 mice). IL-4 or PBS was intrathecally administrated from day 14 to day 16 post-SpNT (once a day for 3 days). ****p&lt;0.0001 versus the ipsilateral side of PBS-treated group, two-way ANOVA with post hoc Tukey multiple comparison test. (<bold>B</bold>) Venus fluorescence (yellow) and P2Y12R and IBA1 immunostaining (magenta and cyan, respectively) in the SDH of <italic>Itgax-Venus</italic> mice with SpNT 21 days after PBS or IL-4 treatment (from day 14â16). Scale bars, 200 Âµm (middle), 100 Âµm (right). (<bold>C</bold>) Colocalization of Venus, P2Y12R, and IBA1. Scale bar, 20 Âµm. (<bold>D</bold>) Flow cytometric quantification for the number of CD11c<sup>+</sup> (CD11b<sup>+</sup>CD45<sup>+</sup>Venus<sup>+</sup>) and total (CD11b<sup>+</sup>CD45<sup>+</sup>) microglia in the 3â4th lumbar SDH contralateral (<bold>C</bold>) and ipsilateral (<bold>I</bold>) to SpNT (n=6â7 mice). One-way ANOVA with post hoc Tukey multiple comparison test. Data are shown as mean Â± SEM.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1âsource data 1.</label><caption><title>Raw numerical values for <xref ref-type="fig" rid="fig1">Figure 1</xref> plots.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-105087-fig1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-105087-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1âfigure supplement 1.</label><caption><title>Monocytes/macrophages in the SDH and DRG after intrathecal administration of IL-4.</title><p>Immunohistochemical analysis of the SDH (<bold>A</bold>) and the DRG (<bold>B</bold>) of naive WT mice and SpNT-WT mice with intrathecal injection of PBS or IL-4 (from day 14â16 post-SpNT). Immunofluorescence of CD169, CD11b, P2Y12R, and IBA1 in the SDH (<bold>L4</bold>) ipsilateral to the SpNT (day 17) (<bold>A</bold>) and of CCR2 and IBA1 in the DRG (<bold>L4</bold>) ipsilateral to the SpNT (day 17) (<bold>B</bold>). Scale bars, 100 Î¼m (<bold>A</bold>) and 40 Î¼m (<bold>B</bold>).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-105087-fig1-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-2"><title>IL-4-induced remission of pain hypersensitivity requires spinal CD11c<sup>+</sup> microglia</title><p>To determine whether CD11c<sup>+</sup> microglia are required for pain remission induced by IL-4, we used <italic>Itgax-DTR-EGFP</italic> mice in which the diphtheria toxin (DTX) receptor (DTR) and enhanced green fluorescence protein (EGFP) are expressed on CD11c<sup>+</sup> cells (<xref ref-type="bibr" rid="bib26">Kohno et al., 2022</xref>; <xref ref-type="bibr" rid="bib22">Jung et al., 2002</xref>), and administered DTX intrathecally to these mice to deplete CD11c<sup>+</sup> microglia in the spinal cord. Intrathecal IL-4 also induced behavioral remission of mechanical hypersensitivity in <italic>Itgax-DTR-EGFP</italic> mice, but the pain-reducing effect was eliminated by intrathecal injection of DTX on day 17 post-SpNT (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). The depletion of EGFP<sup>+</sup> (CD11c<sup>+</sup>) microglia in the SDH by DTX injection was confirmed (<xref ref-type="fig" rid="fig2">Figure 2B</xref>), indicating the necessity of spinal CD11c<sup>+</sup> microglia for the pain-relieving effect of intrathecal IL-4. IL-4 also alleviated pain hypersensitivity in female mice, which was also dependent on CD11c<sup>+</sup> microglia (<xref ref-type="fig" rid="fig3">Figure 3</xref>). In addition to SDH, CD11c<sup>+</sup> cells have been shown to be present at the site of injury and in the DRG (<xref ref-type="bibr" rid="bib26">Kohno et al., 2022</xref>). Thus, we examined the involvement of CD11c<sup>+</sup> cells in the DRG in the pain-relieving effect of intrathecal IL-4 using our previously reported strategy that enables the selective depletion of CD11c<sup>+</sup> cells in the periphery (<xref ref-type="bibr" rid="bib26">Kohno et al., 2022</xref>). The intraperitoneal administration of DTX at a low dose (2 ng/g mouse) in SpNT mice treated with IL-4 on day 17 efficiently eliminated CD11c<sup>+</sup> cells (also positive for IBA1) in the DRG on day 18 (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). However, the number of CD11c<sup>+</sup> microglia in the SDH was not significantly different between the PBS- and DTX-treated groups (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). Under these conditions, we found that the elevated PWT observed in IL-4-treated mice on day 17 did not change 1 day after intraperitoneal administration of DTX (day 18; <xref ref-type="fig" rid="fig4">Figure 4C</xref>), suggesting that CD11c<sup>+</sup> cells in the DRG are not involved in the IL-4-induced alleviating effect on neuropathic pain. Altogether, these data indicate that intrathecally administered IL-4 induces spinal microglia to be in a CD11c<sup>+</sup> state, and that this induction is necessary for the ameliorating effect of IL-4 on neuropathic pain.</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>IL-4-induced remission of pain hypersensitivity requires spinal CD11c<sup>+</sup> microglia.</title><p>(<bold>A</bold>) Paw withdrawal threshold (PWT) of <italic>Itgax-DTR-EGFP</italic> mice before (Pre) and after SpNT (n=6â7 mice). IL-4 or PBS was intrathecally administrated from days 14â16 post-SpNT (once a day for 3 days). On day 17, DTX (0.5 ng/mouse) or PBS was intrathecally injected. ****p&lt;0.0001 versus the ipsilateral side of PBS-PBS group, <sup>â â â â </sup>p&lt;0.0001 versus the ipsilateral side of IL-4-PBS group, two-way ANOVA with post hoc Tukey multiple comparison test. (<bold>B</bold>) Flow cytometric quantification for the number of CD11c<sup>+</sup> microglia (CD11b<sup>+</sup>CD45<sup>+</sup>EGFP<sup>+</sup>) in the 3â4th lumbar SDH contralateral (<bold>C</bold>) and ipsilateral (<bold>I</bold>) to SpNT in <italic>Itgax-DTR-EGFP</italic> mice treated with PBS/PBS, IL-4/PBS, or IL-4/DTX (n=4â5 mice). One-way ANOVA with post hoc Tukey multiple comparison test. Data are shown as mean Â± SEM.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2âsource data 1.</label><caption><title>Raw numerical values for <xref ref-type="fig" rid="fig2">Figure 2</xref> plots.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-105087-fig2-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-105087-fig2-v1.tif"/></fig><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>IL-4 alleviates pain hypersensitivity in female mice.</title><p>Paw withdrawal threshold (PWT) of <italic>Itgax-DTR-EGFP</italic> mice before (Pre) and after SpNT (n=6 female mice). IL-4 or PBS was intrathecally administrated from days 14â16 post-SpNT (once a day for 3 days). On day 17, DTX (0.5 ng/mouse) or PBS was intrathecally injected. ****p&lt;0.0001 versus the ipsilateral side of PBS-PBS group, <sup>â â â </sup>p&lt;0.001 versus the ipsilateral side of IL-4-PBS group, two-way ANOVA with post hoc Tukey multiple comparison test. Data are shown as mean Â± SEM.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3âsource data 1.</label><caption><title>Raw numerical values for <xref ref-type="fig" rid="fig3">Figure 3</xref> plots.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-105087-fig3-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-105087-fig3-v1.tif"/></fig><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>CD11c<sup>+</sup> cells in the DRG are involved in IL-4-induced remission of pain hypersensitivity.</title><p>(<bold>A </bold>and <bold>B</bold>) Immunohistochemical analyses of CD11c<sup>+</sup> cells (EGFP<sup>+</sup> IBA1<sup>+</sup>) in the DRG (<bold>A</bold>) and SDH (<bold>B</bold>) on day 18 post-SpNT of <italic>Itgax-DTR-EGFP</italic> mice treated intrathecally with IL-4 (from days 14 to 16) (n=4â5 mice). DTX (2 ng/g) or PBS was intraperitoneally injected on day 17. The myeloid marker IBA1 was also stained in the SDH (<bold>B</bold>). Scale bars, 100 Âµm. Unpaired t-test. (<bold>C</bold>) Effect of DTX (2 ng/g) intraperitoneally injected (on day 17) on PWT of SpNT mice treated intrathecally with PBS or IL-4 (from days 14 to 16) (n=5 mice). Data are shown as mean Â± SEM.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4âsource data 1.</label><caption><title>Raw numerical values for <xref ref-type="fig" rid="fig4">Figure 4</xref> plots.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-105087-fig4-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-105087-fig4-v1.tif"/></fig></sec><sec id="s2-3"><title>CD11c<sup>+</sup> microglia appearance in the SDH is blunted in SNI model</title><p>To extend the therapeutic potential of CD11c<sup>+</sup> microglia induced by IL-4 in neuropathic pain, we employed another model of neuropathic pain [speared nerve injury (SNI); transection of tibial and common peroneal nerves] (<xref ref-type="bibr" rid="bib11">Decosterd and Woolf, 2000</xref>). Consistent with previous data (<xref ref-type="bibr" rid="bib11">Decosterd and Woolf, 2000</xref>), SNI induced a long-lasting pain-hypersensitive state without spontaneous remission, at least until the last day of testing (day 56 post-SNI; <xref ref-type="fig" rid="fig5">Figure 5A</xref>), which was in stark contrast to the time course of pain hypersensitivity in the SpNT model. We found that the number of CD11c<sup>+</sup> microglia in the SDH at 14 days after nerve injury was lower in the SNI model than in the SpNT model (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). Quantitative analysis by flow cytometry confirmed that there were fewer CD11c<sup>+</sup> SDH microglia in the SNI mice (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). A blunted appearance was also observed on days 35 and 56 post-SNI. In contrast, the total number of microglia in the SDH was comparable between the two models at all time points tested, suggesting an impairment of the nerve injury-induced appearance of CD11c<sup>+</sup> microglia in the SNI model. Furthermore, insulin-like growth factor 1 (IGF1) has been identified as a factor that is highly expressed in CD11c<sup>+</sup> microglia and is necessary for their pain-remitting effect (<xref ref-type="bibr" rid="bib26">Kohno et al., 2022</xref>). We quantified <italic>Igf1</italic> mRNA expression in the spinal tissue or fluorescence-activated cell sorting (FACS)-isolated SDH microglia from nerve-injured mice (<xref ref-type="fig" rid="fig6">Figure 6</xref>). While <italic>Igf1</italic> expression in sorted microglia increased in both models after injury, its levels were lower in microglia from SNI mice than in those from SpNT mice (<xref ref-type="fig" rid="fig6">Figure 6D</xref>). In addition, an increase in <italic>Igf1</italic> mRNA expression in the tissue homogenate of the upper half of the SDH, where CD11c<sup>+</sup> microglia accumulate (<xref ref-type="bibr" rid="bib26">Kohno et al., 2022</xref>), was not observed in tissues from the SNI model (<xref ref-type="fig" rid="fig6">Figure 6E</xref>). Moreover, in FACS-isolated CD11c<sup>high</sup> SDH microglia that highly expressed IGF1, the expression of <italic>Igf1</italic> mRNA was significantly lower in the SNI model (<xref ref-type="fig" rid="fig6">Figure 6F</xref>). Thus, given that either the depletion of CD11c<sup>+</sup> microglia or knockout of their IGF1 prevents the spontaneous remission of pain in the SpNT model (<xref ref-type="bibr" rid="bib26">Kohno et al., 2022</xref>), the long-lasting pain-hypersensitive state in the SNI model could be related to the blunted increase in CD11c<sup>+</sup> microglia in the SDH and their lower expression of IGF1.</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Blunted appearance of CD11c<sup>+</sup> microglia in the SDH after SNI.</title><p>(<bold>A</bold>) PWT of wild-type (WT) mice before (Pre) and after SpNT and SNI (n=5 mice). (<bold>B</bold>) Venus (yellow) and IBA1 immunostaining (magenta) in the SDH of SpNT and SNI mice on day 14. Scale bar, 200 Âµm. (<bold>C</bold>) Flow cytometric quantification of the number of CD11c<sup>+</sup> (CD11b<sup>+</sup>CD45<sup>+</sup>Venus<sup>+</sup>) and total (CD11b<sup>+</sup>CD45<sup>+</sup>) microglia in the 3â4th lumbar SDH of <italic>Itgax-Venus</italic> mice after SpNT and SNI (n=3â5 mice). ****p&lt;0.0001 versus the ipsilateral side of the SNI group, two-way ANOVA with post hoc Tukey multiple comparison test. Data are shown as mean Â± SEM.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5âsource data 1.</label><caption><title>Raw numerical values for <xref ref-type="fig" rid="fig5">Figure 5</xref> plots.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-105087-fig5-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-105087-fig5-v1.tif"/></fig><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Expression of Igf1 is lower in the SNI model.</title><p>(<bold>AâC</bold>) <italic>Igf1</italic> mRNA in total RNA extracted from sorted SDH microglia (<italic>A</italic>; n=4 mice), from tissue homogenate of the upper half of the SDH (<italic>B</italic>; n=3â4 mice), or from the sorted CD11c<sup>high</sup> microglia (<italic>C</italic>; n=5â6 mice) in <italic>Itgax-Venus</italic> mice was quantified by qPCR on day 36 post-SpNT or SNI. Cells and tissues were collected from the contralateral (<bold>C</bold>) and ipsilateral (<bold>I</bold>) side to the SpNT or SNI. Values represent the relative ratio of <italic>Igf1</italic> mRNA (normalized to the value for <italic>Actb</italic> mRNA) to the ipsilateral (<bold>A and C</bold>) or contralateral (<bold>B</bold>) side of SpNT mice. One-way ANOVA with post hoc Tukey multiple comparison test (<bold>A and B</bold>). Unpaired t-test (<bold>C</bold>). Data are shown as mean Â± SEM.</p><p><supplementary-material id="fig6sdata1"><label>Figure 6âsource data 1.</label><caption><title>Raw numerical values for <xref ref-type="fig" rid="fig6">Figure 6</xref> plots.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-105087-fig6-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-105087-fig6-v1.tif"/></fig></sec><sec id="s2-4"><title>IL-4 alleviates SNI-induced pain hypersensitivity in CD11c<sup>+</sup> microglia- and IGF1-dependent manners</title><p>Based on the above findings, we tested whether IL-4 could increase the number of CD11c<sup>+</sup> microglia and resolve pain hypersensitivity in the SNI model. Intrathecal treatment with IL-4 in SNI mice from day 14 to day 16 significantly increased the number of CD11c<sup>+</sup> microglia on day 21, almost all of which were positive for IBA1 and P2Y12R (<xref ref-type="fig" rid="fig7">Figure 7AâC</xref>). Similar to the data obtained for SpNT mice, the total number of microglia in the SDH was not significantly different between PBS- and IL-4-treated SNI mice (<xref ref-type="fig" rid="fig7">Figure 7C</xref>). Behaviorally, intrathecal IL-4 treatment alleviated the SNI-induced mechanical hypersensitivity (<xref ref-type="fig" rid="fig7">Figure 7D</xref>). Furthermore, the depletion of CD11c<sup>+</sup> microglia in the SDH of IL-4-treated SNI mice by intrathecal administration of DTX on day 17 negated the ameliorating effect of IL-4 on pain hypersensitivity (<xref ref-type="fig" rid="fig8">Figure 8A and B</xref>). Moreover, the IL-4âs effect was not observed in <italic>Cx3cr1</italic><sup>CreERT2/+</sup>;<italic>Igf1</italic><sup>flox/flox</sup> mice treated with tamoxifen (<xref ref-type="fig" rid="fig8">Figure 8C</xref>), a treatment that enables selective knockout of the <italic>Igf1</italic> gene in tissue-resident <italic>Cx3cr1</italic><sup>+</sup> cells (<xref ref-type="bibr" rid="bib38">Parkhurst et al., 2013</xref>), the majority of which are microglia in the SDH (<xref ref-type="bibr" rid="bib26">Kohno et al., 2022</xref>). Overall, intrathecally administered IL-4 exhibited a pain-remitting effect in the SNI model, which was dependent on CD11c<sup>+</sup> microglia and IGF1.</p><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>IL-4 increases CD11c<sup>+</sup> microglia in the SDH and ameliorates pain hypersensitivity in the SNI mice.</title><p>(<bold>A</bold>) Venus fluorescence (yellow) and P2Y12R and IBA1 immunostaining (magenta and cyan, respectively) in the SDH of <italic>Itgax-Venus</italic> mice with SpNT after PBS or IL-4 treatment. Scale bar, 200 Âµm. (<bold>B</bold>) Colocalization of Venus, P2Y12R, and IBA1. Scale bar, 20 Âµm. (<bold>C</bold>) Flow cytometric quantification for the number of CD11c<sup>+</sup> (CD11b<sup>+</sup>CD45<sup>+</sup>Venus<sup>+</sup>) and total (CD11b<sup>+</sup>CD45<sup>+</sup>) microglia in the 3â4th lumbar SDH contralateral (<bold>C</bold>) and ipsilateral (<bold>I</bold>) to SNI (n=7 mice). One-way ANOVA with post hoc Tukey multiple comparison test. (<bold>D</bold>) Paw withdrawal threshold (PWT) of <italic>Itgax-Venus</italic> mice before (Pre) and after SNI (n=6â8 mice). IL-4 or PBS was intrathecally administrated from days 14 to 16 post-SNI (once a day for 3 days). *p&lt;0.05, ***p&lt;0.001 versus the ipsilateral side of PBS group, two-way ANOVA with post hoc Tukey multiple comparison test. Data are shown as mean Â± SEM.</p><p><supplementary-material id="fig7sdata1"><label>Figure 7âsource data 1.</label><caption><title>Raw numerical values for <xref ref-type="fig" rid="fig7">Figure 7</xref> plots.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-105087-fig7-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-105087-fig7-v1.tif"/></fig><fig id="fig8" position="float"><label>Figure 8.</label><caption><title>IL-4 alleviates SNI-induced pain hypersensitivity in CD11c<sup>+</sup> microglia and IGF1-dependent manners.</title><p>(<bold>A</bold>) Flow cytometric quantification for the number of CD11c<sup>+</sup> microglia (CD11b<sup>+</sup>CD45<sup>+</sup>EGFP<sup>+</sup>) in the 3â4th lumbar SDH contralateral (<bold>C</bold>) and ipsilateral (<bold>I</bold>) to SNI in <italic>Itgax-DTR-EGFP</italic> mice treated with IL-4/PBS or IL-4/DTX (n=6 mice). One-way ANOVA with post hoc Tukey multiple comparison test. (<bold>B</bold>) PWT of <italic>Itgax-DTR-EGFP</italic> mice before (Pre) and after SNI (n=6 mice). IL-4 was intrathecally administrated from days 14 to 16 post-SNI (once a day for 3 days). On day 17, DTX (0.5 ng/mouse) or PBS was intrathecally injected. **p&lt;0.01 versus the ipsilateral side of the IL-4-PBS group, two-way ANOVA with post hoc Tukey multiple comparison test. (<bold>C</bold>) PWT of <italic>Cx3cr1</italic><sup>CreERT2/+</sup>;<italic>Igf1</italic><sup>flox/flox</sup> mice before (Pre) and after SNI (n=5â7 mice). Tamoxifen or vehicle was administered 4 weeks before SNI to induce recombination. IL-4 was intrathecally administered from days 14 to 16 post-SNI (once a day for 3 days). ***p&lt;0.001 versus the ipsilateral side of Corn oil group, two-way ANOVA with post hoc Tukey multiple comparison test. Data are shown as mean Â± SEM.</p><p><supplementary-material id="fig8sdata1"><label>Figure 8âsource data 1.</label><caption><title>Raw numerical values for <xref ref-type="fig" rid="fig8">Figure 8</xref> plots.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-105087-fig8-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-105087-fig8-v1.tif"/></fig></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Increasing evidence indicates that following peripheral nerve injury, microglia in the SDH cause significant changes in morphology, cell number, transcriptional and translational activities, and function (<xref ref-type="bibr" rid="bib18">Inoue and Tsuda, 2018</xref>; <xref ref-type="bibr" rid="bib43">Tansley et al., 2022</xref>; <xref ref-type="bibr" rid="bib41">Shibata et al., 2025</xref>; <xref ref-type="bibr" rid="bib31">Masuda et al., 2012</xref>; <xref ref-type="bibr" rid="bib32">Masuda et al., 2014</xref>). Numerous studies have shown that these changes occurring in the early phase after nerve injury are necessary for the development of neuropathic pain (<xref ref-type="bibr" rid="bib18">Inoue and Tsuda, 2018</xref>; <xref ref-type="bibr" rid="bib31">Masuda et al., 2012</xref>; <xref ref-type="bibr" rid="bib32">Masuda et al., 2014</xref>; <xref ref-type="bibr" rid="bib44">Tsuda et al., 2003</xref>; <xref ref-type="bibr" rid="bib9">Coull et al., 2005</xref>). In contrast to their role, we have recently shown that some SDH microglia in the later phase are changed into CD11c<sup>+</sup> states with different transcriptional and functional profiles and that these microglia are required for spontaneous remission of neuropathic pain (<xref ref-type="bibr" rid="bib26">Kohno et al., 2022</xref>). Thus, CD11c<sup>+</sup> microglia are attracting attention as a potential target for future analgesics (<xref ref-type="bibr" rid="bib42">Sideris-Lampretsas and Malcangio, 2022</xref>; <xref ref-type="bibr" rid="bib45">Tsuda et al., 2023</xref>). In this study, we demonstrated for the first time that CD11c<sup>+</sup> microglia are an essential target of IL-4 administered intrathecally to induce the behavioral remission of pain hypersensitivity. The pharmacological effect of intrathecal IL-4 appears to be mediated by its direct action on spinal microglia, as the expression of IL-4RÎ± in the SDH has been shown to be predominant in microglia after nerve injury (<xref ref-type="bibr" rid="bib37">Okutani et al., 2018</xref>). This is also supported by the data that activation of STAT6 (the downstream molecule of IL-4RÎ±) after intrathecal IL-4 selectively occurs in spinal microglia (<xref ref-type="bibr" rid="bib37">Okutani et al., 2018</xref>) and that primary cultured microglia treated with IL-4 become CD11c<sup>+</sup> and express IGF1 (<xref ref-type="bibr" rid="bib2">Butovsky et al., 2006</xref>; <xref ref-type="bibr" rid="bib6">Chiu et al., 2008</xref>; <xref ref-type="bibr" rid="bib1">Butovsky et al., 2005</xref>). Furthermore, based on our data showing that IL-4 increased the number of CD11c<sup>+</sup> microglia without affecting the total number of microglia, it is conceivable that IL-4 acts on microglia and changes their state to CD11c<sup>+</sup> microglia (rather than the proliferation of CD11c<sup>+</sup> microglia themselves), leading to behavioral remission of neuropathic pain.</p><p>Intrathecal IL-4 administration also increased CD11c<sup>+</sup> microglia in the SDH contralateral to SpNT but did not change the PWT in the contralateral hindpaw. This gap seems to be related to the selective effect of CD11c<sup>+</sup> microglia and their factors (especially IGF1) on pathologically heightened pain sensitivity. In fact, depletion of CD11c<sup>+</sup> spinal microglia and intrathecal administration of IGF1 do not elevate pain threshold of the contralateral hindpaw (<xref ref-type="bibr" rid="bib26">Kohno et al., 2022</xref>).</p><p>In addition to SDH, the peripheral effects of IL-4 on neuropathic pain have been reported in several pain models. IL-4 applied to injured peripheral nerves, such as sciatic nerves, ameliorates neuropathic mechanical hypersensitivity (<xref ref-type="bibr" rid="bib24">Kiguchi et al., 2015</xref>). In sciatic nerves, IL-4RÎ± expression is upregulated in macrophages that accumulate in injured nerves (<xref ref-type="bibr" rid="bib24">Kiguchi et al., 2015</xref>). Intrathecally administered IL-4 may affect cells in the DRG, since chemokine (C-C motif) receptor 2 (CCR2)<sup>+</sup> monocytes were increased in the capsule of the DRG after IL-4 treatment (<xref ref-type="fig" rid="fig1s1">Figure 1âfigure supplement 1B</xref>). The involvement of these monocytes in the DRG in IL-4-induced alleviation of neuropathic pain is unclear and warrants further investigation. However, our findings obtained from mice with depletion of CD11c<sup>+</sup> IBA1<sup>+</sup> cells (presumably macrophages) in the DRG (but not SDH) suggest that the cells required for intrathecal IL-4 to ameliorate pain hypersensitivity are CD11c<sup>+</sup> microglia in the SDH, but not peripheral CD11c<sup>+</sup> macrophages. Furthermore, perineurally administered IL-4 can act on macrophages, which leads to a change in their state from pro- to anti-inflammatory via a STAT6-dependent mechanism (<xref ref-type="bibr" rid="bib24">Kiguchi et al., 2015</xref>) and further to a release of opioid peptides that are key factors in the suppression of neuropathic pain (<xref ref-type="bibr" rid="bib4">Celik et al., 2020</xref>). In the SDH, IGF1 appears to be necessary for the pain-relieving effect of CD11c<sup>+</sup> microglia induced by IL-4. This is supported by data obtained from microglia-selective IGF1-knockout mice (<italic>Cx3cr1</italic><sup>CreERT2/+</sup>;<italic>Igf1</italic><sup>flox/flox</sup> mice treated with tamoxifen). Although <italic>Cx3cr1</italic><sup>+</sup> cells, other than CD11c<sup>+</sup> microglia, also lack <italic>Igf1</italic> in these mice, given <italic>Igf1</italic> expression is much higher in CD11c<sup>+</sup> microglia than in CD11c<sup>neg</sup> microglia (<xref ref-type="bibr" rid="bib26">Kohno et al., 2022</xref>), IGF1 from CD11c<sup>+</sup> microglia would play an important role in IL-4-induced pain remission. Thus, while IL-4 acts on macrophages and microglia in the DRG/injured nerves and the SDH, respectively, the molecular basis of its ameliorating effects on neuropathic pain hypersensitivity is different.</p><p>Another notable finding of this study was that the emergence of CD11c<sup>+</sup> spinal microglia following nerve injury was impaired in the SNI model, which did not exhibit spontaneous remission of behavioral pain hypersensitivity. This raises the possibility that the reduced ability of spinal microglia to shift toward the CD11c<sup>+</sup> state in the SNI model contributes, at least in part, to long-lasting pain hypersensitivity because SpNT mice with depleted CD11c<sup>+</sup> spinal microglia have been shown to exhibit persistent pain hypersensitivity (<xref ref-type="bibr" rid="bib26">Kohno et al., 2022</xref>). Considering our finding that the total number of spinal microglia was comparable between the SpNT and SNI models, the signal(s) for microglia to transition to the CD11c<sup>+</sup> state, rather than to the initial activation after nerve injury, could be different in these models. The mechanisms underlying this difference require further investigation, but we highlight that even under such conditions, IL-4 administered intrathecally induces the appearance of CD11c<sup>+</sup> microglia in the SDH and exerts a pain-remitting effect in a manner that is dependent on CD11c<sup>+</sup> microglia. These data suggest that spinal microglia in the SNI model retain the ability to respond to IL-4, allowing microglia to be in a CD11c<sup>+</sup> state that remits neuropathic pain and broadly extends their therapeutic potential to neuropathic pain.</p><p>In this study, we showed an ability of IL-4, known as a T-cell-derived factor, to increase CD11c<sup>+</sup> microglia and to control neuropathic pain. Recent studies have also indicated that immune cells such as CD8<sup>+</sup> T cells infiltrating into spinal cord (<xref ref-type="bibr" rid="bib12">Fan et al., 2025</xref>), and regulatory T cells (<xref ref-type="bibr" rid="bib27">Kuhn et al., 2021</xref>; <xref ref-type="bibr" rid="bib34">Midavaine et al., 2025</xref>) and MRC1<sup>+</sup> macrophages (<xref ref-type="bibr" rid="bib36">Niehaus et al., 2021</xref>) in the spinal meninges have important roles in controlling microglial states and neuropathic pain. Thus, these findings provide new insights into the mechanisms of the neuro-immune interactions that regulate neuropathic pain. Furthermore, our data, demonstrating that IL-4 increases CD11c<sup>+</sup> microglia without affecting the total number of microglia, could open a new avenue for developing strategies to modulate microglial subpopulations through molecular targeting, which may lead to new analgesics. However, given IL-4âs association with allergic responses, further investigation of the specific signaling pathways and molecular processes by which IL-4 induces a transition of spinal microglia to the CD11c<sup>+</sup> state may provide clues to discovering new targets that offer more selective and safer therapeutic approaches. Moreover, since CD11c<sup>+</sup> microglia have been implicated in other CNS diseases (e.g. Alzheimer disease <xref ref-type="bibr" rid="bib23">Keren-Shaul et al., 2017</xref>, amyotrophic lateral sclerosis <xref ref-type="bibr" rid="bib49">Xie et al., 2022</xref>, and multiple sclerosis <xref ref-type="bibr" rid="bib48">Wlodarczyk et al., 2018</xref>), further investigations into the mechanisms driving CD11c<sup>+</sup> microglia induction could provide insights into novel therapeutic strategies not only for neuropathic pain but also for other CNS diseases.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Strain, strain background (include species and sex here)</td><td align="left" valign="bottom">C57BL/6 J</td><td align="left" valign="bottom">The Jackson Laboratory Japan</td><td align="left" valign="bottom">NA</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Genetic reagent (include species here)</td><td align="left" valign="bottom">B6.Cg-Tg(Itgax-Venus)Mnz/J</td><td align="left" valign="bottom">Jackson Laboratory</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:IMSR_JAX:008829">IMSR_JAX:008829</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Genetic reagent (include species here)</td><td align="left" valign="bottom">B6.FVB-1700016L21RikTg(Itgax-DTR/EGFP)57Lan/J</td><td align="left" valign="bottom">Jackson Laboratory</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:IMSR_JAX:004509">IMSR_JAX:004509</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Genetic reagent (include species here)</td><td align="left" valign="bottom">B6.129P2(Cg)-Cx3cr1tm2.1(cre/ERT2)Litt/WganJ</td><td align="left" valign="bottom">Jackson Laboratory</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:IMSR_JAX:021160">IMSR_JAX:021160</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Genetic reagent (include species here)</td><td align="left" valign="bottom">B6.129(FVB)-Igf1tm1Dlr/J</td><td align="left" valign="bottom">Jackson Laboratory</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:IMSR_JAX:016831">IMSR_JAX:016831</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Guinea pig anti-IBA1</td><td align="left" valign="bottom">Synaptic Systems</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2924932">AB_2924932</ext-link></td><td align="left" valign="bottom">1:2000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rabbit anti-P2Y12R</td><td align="left" valign="bottom">AnaSpec</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2298886">AB_2298886</ext-link></td><td align="left" valign="bottom">1:2000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rabbit anti-GFP</td><td align="left" valign="bottom">MBL International</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_591819">AB_591819</ext-link></td><td align="left" valign="bottom">1:1000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">APC anti-mouse CD169</td><td align="left" valign="bottom">Biolegend</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2565640">AB_2565640</ext-link></td><td align="left" valign="bottom">1:500</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rabbit anti-CCR2</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2893307">AB_2893307</ext-link></td><td align="left" valign="bottom">1:500</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Goat Anti-Guinea pig IgG H&amp;L (Alexa Fluor 405)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2827755">AB_2827755</ext-link></td><td align="left" valign="bottom">1:1000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Goat anti-Rabbit IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor 488</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2576217">AB_2576217</ext-link></td><td align="left" valign="bottom">1:1000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Goat anti-Rabbit IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor 546</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2534093">AB_2534093</ext-link></td><td align="left" valign="bottom">1:1000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat Anti-CD16 /CD32 Monoclonal Antibody, Unconjugated, Clone 2.4G2</td><td align="left" valign="bottom">BD Biosciences</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_394657">AB_394657</ext-link></td><td align="left" valign="bottom">1:200</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat Anti-CD11b Monoclonal Antibody, Alexa Fluor 647 Conjugated, Clone M1/70</td><td align="left" valign="bottom">BD Biosciences</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_396796">AB_396796</ext-link></td><td align="left" valign="bottom">1:1000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">PE anti-mouse CD45</td><td align="left" valign="bottom">âBioLegend</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_312971">AB_312971</ext-link></td><td align="left" valign="bottom">1:1000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Brilliant Violet 785(TM) anti-mouse/human CD11b</td><td align="left" valign="bottom">âBioLegend</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2561373">AB_2561373</ext-link></td><td align="left" valign="bottom">1:1000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">APC anti-mouse CD206 (MMR)</td><td align="left" valign="bottom">âBioLegend</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_10900231">AB_10900231</ext-link></td><td align="left" valign="bottom">1:200</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">Recombinant Murine IL-4</td><td align="left" valign="bottom">âPeproTech</td><td align="left" valign="bottom">214â14</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Myelin Removal Beads II</td><td align="left" valign="bottom">Miltenyi Biotec</td><td align="left" valign="bottom">130-096-433</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">MACS LS column</td><td align="left" valign="bottom">Miltenyi Biotec</td><td align="left" valign="bottom">130-042-401</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Quick-RNA Micro-Prep kit</td><td align="left" valign="bottom">ZYMO</td><td align="left" valign="bottom">R1051</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Trisure</td><td align="left" valign="bottom">Bioline</td><td align="left" valign="bottom">BIO-38032</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Prime Script reverse transcriptase</td><td align="left" valign="bottom">Takara</td><td align="left" valign="bottom">2680B</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Premix Ex Taq (Probe qPCR)</td><td align="left" valign="bottom">Takara</td><td align="left" valign="bottom">RR390B</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">tamoxifen</td><td align="left" valign="bottom">SIGMA</td><td align="left" valign="bottom">T5648</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Diphtheria Toxin Solution</td><td align="left" valign="bottom">Wako</td><td align="left" valign="bottom">048â34371</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">collagenase D</td><td align="left" valign="bottom">Roche</td><td align="left" valign="bottom">11088866001</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">dispase</td><td align="left" valign="bottom">GIBCO</td><td align="left" valign="bottom">17105041</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">RNAlater</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">AM7021</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">7-aminoactinomycin D</td><td align="left" valign="bottom">Miltenyi Biotec</td><td align="left" valign="bottom">170-081-088</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">LSM700 Imaging System</td><td align="left" valign="bottom">Carl Zeiss</td><td align="left" valign="bottom">NA</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">CytoFLEX SRT</td><td align="left" valign="bottom">Beckman Coulter</td><td align="left" valign="bottom">NA</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">FlowJo</td><td align="left" valign="bottom">BD</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:SCR_008520">SCR_008520</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">FACSAria III</td><td align="left" valign="bottom">BD Biosciences</td><td align="left" valign="bottom">NA</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">QuantStudio 3</td><td align="left" valign="bottom">Applied Biosystems</td><td align="left" valign="bottom">NA</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Prism 7</td><td align="left" valign="bottom">âGraphPad</td><td align="left" valign="bottom">NA</td><td align="left" valign="bottom"/></tr></tbody></table></table-wrap><sec id="s4-1"><title>Mice</title><p>C57BL/6 mice were purchased from Charles River Japan (Kanagawa, Japan). <italic>Itgax-Venus</italic> mice (B6.Cg-Tg(<italic>Itgax-Venus</italic>)Mnz/J) (<xref ref-type="bibr" rid="bib29">Lindquist et al., 2004</xref>), <italic>Itgax-DTR-EGFP</italic> mice (B6.FVB-1700016L21Rik<italic><sup>Tg(Itgax-DTR/EGFP)57Lan/J</sup></italic>) (<xref ref-type="bibr" rid="bib22">Jung et al., 2002</xref>), <italic>Cx3cr1</italic><sup>CreERT2/+</sup> mice (B6.129P2(Cg)-<italic>Cx3cr1<sup>tm2.1(cre/ERT2)Litt</sup></italic>/WganJ) (<xref ref-type="bibr" rid="bib38">Parkhurst et al., 2013</xref>), <italic>Igf1</italic><sup>flox/flox</sup> mice (B6.129(FVB)-<italic>Igf1<sup>tm1Dlr</sup></italic>/J) <xref ref-type="bibr" rid="bib30">Liu et al., 1998</xref> were purchased from Jackson Laboratory (Bar Harbor, ME). The data were obtained from male mice except for the data shown in <xref ref-type="fig" rid="fig1">Figures 1D</xref>, <xref ref-type="fig" rid="fig3">3</xref> and <xref ref-type="fig" rid="fig7">7C</xref>. For induction of Cre recombinase, <italic>Cx3cr1</italic><sup>CreERT2/+</sup>; <italic>Igf1</italic><sup>flox/flox</sup> mice were injected subcutaneously with 4 mg of tamoxifen (Sigma, St. Louis, MO) dissolved in 200 Î¼L corn oil (Wako, Osaka, Japan) twice with a 48 hr interval. Four weeks later, when gene-deleting CX3CR1<sup>+</sup> cells in peripheral tissues including the DRG has been shown to be replaced by non-deleting cells (<xref ref-type="bibr" rid="bib38">Parkhurst et al., 2013</xref>; <xref ref-type="bibr" rid="bib39">Peng et al., 2016</xref>), the mice were subjected to nerve injury. All mice used were aged 5â14 weeks at the start of each experiment and were housed individually or in groups at a temperature of 22 Â± 1Â°C with a 12 hr lightâdark cycle and were fed food and water ad libitum. All animal experiments were conducted according to relevant national and international guidelines contained in the âAct on Welfare and Management of Animalsâ (Ministry of Environment of Japan) and âRegulation of Laboratory Animalsâ (Kyushu University) and under the protocols approved by the Institutional Animal Care and Use committee review panels at Kyushu University.</p></sec><sec id="s4-2"><title>Peripheral nerve injury</title><p>We used two injury models, spinal nerve transection (SpNT) (<xref ref-type="bibr" rid="bib26">Kohno et al., 2022</xref>; <xref ref-type="bibr" rid="bib33">Masuda et al., 2017</xref>), which is a modified spinal nerve injury model (<xref ref-type="bibr" rid="bib16">Ho Kim and Mo Chung, 1992</xref>), and spared nerve injury (SNI) (<xref ref-type="bibr" rid="bib11">Decosterd and Woolf, 2000</xref>). For the SpNT model, under isoflurane (2%) anesthesia, a small incision at L3âS1 was made. The paraspinal muscle and fat were removed from the L5 transverse process, which exposed the parallel-lying L3 and L4 spinal nerves. The L4 nerve was then carefully isolated and cut while leaving the L3 spinal nerve intact. The wound and the surrounding skin were sutured with 5â0 silk. For the SNI model, according to a previously reported method (<xref ref-type="bibr" rid="bib7">Cichon et al., 2018</xref>), under isoflurane (2%) anesthesia, the skin on the left thigh was open, and terminal branches of the sciatic nerve were exposed by separating the thigh muscle layer using scissors and blunt forceps. Two of the three branches, the tibial and common peroneal nerves, were tightly ligated with 7â0 Nylon (NM-01, WASHIESU MEDICAL), and a small portion of the nerves distal to the ligation was removed while leaving the sural nerve intact. The wound and the surrounding skin were sutured with 5â0 silk.</p></sec><sec id="s4-3"><title>Immunohistochemistry</title><p>According to our previously reported method (<xref ref-type="bibr" rid="bib26">Kohno et al., 2022</xref>), mice were deeply anesthetized by i.p. injection of pentobarbital and perfused transcardially with phosphate buffered saline (PBS) followed by ice-cold 4% paraformaldehyde/PBS. Transverse L4 spinal cord sections (30 Î¼m) or L4 dorsal root ganglion (DRG) sections (20 Î¼m) were incubated for 48 hr at 4 Â°C with primary antibody for IBA1 (1:2000; Cat# 234 308, Synaptic Systems), P2Y12R (1:2000; Cat# AS-55043A, AnaSpec), CCR2 (1:500; Cat# ab273050, Abcam), APC-conjugated CD169 (1:500, Cat# 142417, Biolegend), PE-conjugated CD11b (1:1000, Cat# 101207, Biolegend), or GFP (1:1000; Cat# 598, MBL Life science). Tissue sections were incubated with secondary antibodies conjugated to Alexa Fluor 405 (1:1000, Abcam), 488, or 546 (1:1000, Molecular Probes) and mounted with Vectashield. Three to five sections from one tissue were randomly selected and analyzed using an LSM700 Imaging System (Carl Zeiss, Japan).</p></sec><sec id="s4-4"><title>Behavioral test</title><p>To assess mechanical sensitivity, calibrated von Frey filaments (0.02â2.0 g, North Coast Medical, USA) were applied to the plantar surfaces of the hindpaws of mice with or without PNI (<xref ref-type="bibr" rid="bib26">Kohno et al., 2022</xref>) and the 50% PWT was determined using the upâdown method (<xref ref-type="bibr" rid="bib5">Chaplan et al., 1994</xref>).</p></sec><sec id="s4-5"><title>Intrathecal injection</title><p>Under 2% isoflurane anesthesia, a 30 G needle attached to a 25 Î¼L Hamilton syringe was inserted into the intervertebral space between L5 and L6 spinal vertebrae in mice, as previously described (<xref ref-type="bibr" rid="bib26">Kohno et al., 2022</xref>; <xref ref-type="bibr" rid="bib17">Hylden and Wilcox, 1980</xref>). Recombinant Murine IL-4 was purchased from Peprotech (Cat# 214â14). IL-4 (40 ng/Î¼L in PBS, 5 Î¼L/mouse) or PBS as a control was intrathecally injected once a day for 3 days from day 14 post-PNI. DTX was purchased from Wako (Cat# 048â34371) and was injected intrathecally (0.1 ng/Î¼L in PBS, 5 Î¼L/mouse) or intraperitoneally (2 ng/g mouse) into <italic>Itgax-DTR-EGFP</italic> mice. Only mice whose hypersensitivity was attenuated by IL-4 treatment were used for the DTX-induced cell depletion experiment shown in <xref ref-type="fig" rid="fig4">Figure 4C</xref> (10 out of 12 mice were included) and <xref ref-type="fig" rid="fig8">Figure 8B</xref> (12 out of 15 mice were included).</p></sec><sec id="s4-6"><title>Flow cytometry</title><p>As previously described (<xref ref-type="bibr" rid="bib26">Kohno et al., 2022</xref>), mice were deeply anesthetized by i.p. injection of pentobarbital and perfused transcardially with PBS to remove the circulating blood from the vasculature. The spinal cord was rapidly and carefully removed from the vertebral column and placed into ice-cold Hanksâ balanced salt solution (HBSS). The 3rdâ4th lumbar (L3/4) segments (2 mm long) of the spinal dorsal horn (SDH) ipsilateral and contralateral to nerve injury were separated. Unilateral spinal tissue pieces were treated with pre-warmed 0.8 mL enzymatic solution [0.2 U/mL collagenase D (Cat# 11088866001; Roche) and 4.3 U/mL dispase (Cat# 17105041; GIBCO)] in HBSS containing 2% fetal bovine serum (FBS) for 30 min at 37 Â°C. The tissues were homogenized by passing through a 23 G needle attached with a 1 mL syringe and were further incubated for 15 min at 37 Â°C. After that, the tissues were homogenized by passing twice through a 26 G needle, and the enzymatic reaction was stopped by adding EDTA (0.5 M). To count the number of CD11c<sup>+</sup> (Venus<sup>+</sup> or EGFP<sup>+</sup>) microglia, cell suspension was blocked by incubating with Fc Block (Cat# 553142; BD Biosciences) for 5 min at 4 Â°C and immunostained with CD11b-AlexaFluor 647 (M1/70; 1:1000; Cat# 557686, BD Biosciences) and CD45-PE (1:1000; Cat# 103106, Biolegend) for 30 min at 4 Â°C in the dark. After washing, the pellet was resuspended in ice-cold HBSS-FBS and filtered through a 35 Î¼m nylon cell strainer (BD Biosciences) to isolate tissue debris from the cell suspension. The total number of microglia (CD11b<sup>+</sup> CD45<sup>+</sup> cells) in the L3/4 spinal cord or SDH was analyzed using CytoFLEX SRT (Beckman Coulter) and FlowJo software (TreeStar). Microglia with Venus fluorescence higher in intensity than that observed in microglia of wild-type mice were analyzed as CD11c<sup>+</sup> microglia.</p></sec><sec id="s4-7"><title>Fluorescent-activated cell sorting (FACS)</title><p>Spinal tissues were removed and homogenized as described above. Myelin debris was removed from the cell suspension using Myelin Removal Beads II and a MACS LS column (Miltenyi Biotec, Bergisch-Gladbach, Germany) according to the manufacturerâs protocol and our previously reported method (<xref ref-type="bibr" rid="bib26">Kohno et al., 2022</xref>). After centrifugation (300 Ã <italic>g</italic>, 10 min, 4 Â°C), the cells were resuspended in HBSS containing 10% FBS. The cell suspension was blocked by incubating with Fc Block and immunostained with CD11b-Brilliant Violet 785 (1:1000; Cat# 101243, BioLegend), CD206-APC (1:200; Cat# 141708, BioLegend), and CD45-PE (1:1000; Cat# 103105, BioLegend) for 30 min at 4 Â°C in the dark. After washing, cell suspension was treated with 7-aminoactinomycin D (7-AAD; Miltenyi Biotec) and incubated for 10 min on ice for viability staining prior to cell sorting. CD11b<sup>+</sup> CD45<sup>+</sup> CD206<sup>neg</sup> 7-AAD<sup>neg</sup>-singlet cells are gated as live microglia and sorted using FACSAria III (BD Biosciences) or CytoFLEX SRT. The sorted cells were directly collected in lysis buffer for total RNA extraction using the Quick-RNA Micro-Prep kit (ZYMO). CD11c<sup>high</sup> microglia were collected as cells with Venus fluorescence higher than the median Venus fluorescence of all CD11c<sup>+</sup> microglia (<xref ref-type="bibr" rid="bib26">Kohno et al., 2022</xref>).</p></sec><sec id="s4-8"><title>mRNA extraction from spinal cord homogenates</title><p>Mice were deeply anesthetized by pentobarbital and perfused transcardially with ice-cold PBS followed by RNAlater Stabilization Solution (Cat# AM7021, Invitrogen). The isolated SDH tissue around the boundary between L3 and L4 segments was isolated and separated into the ipsilateral and contralateral sides, and the upper half portion of the SDH of each side was dissected as described previously (<xref ref-type="bibr" rid="bib26">Kohno et al., 2022</xref>). Total RNA was extracted from tissue homogenates using Trisure (CAT# BIO-38032, Bioline, USA) according to manufacturerâs protocol and purified with the Quick-RNA Micro-Prep kit (ZYMO).</p></sec><sec id="s4-9"><title>QPCR</title><p>As described previously (<xref ref-type="bibr" rid="bib26">Kohno et al., 2022</xref>), the extracted RNA from the sorted cells or the tissue was transferred to reverse transcriptional reaction with Prime Script reverse transcriptase (2680B, Takara, Japan). Quantitative PCR (qPCR) was performed with Premix Ex Taq (Cat# RR390B, Takara, Japan) using QuantStudio 3 (Applied Biosystems, USA). Expression levels were normalized to the values for <italic>Actb</italic>. The sequences of TaqMan primer pairs and probe are described below: <italic>Actb</italic>: 5â-FAM-<named-content content-type="sequence">CCTGGCCTCACTGTCCACCTTCCA</named-content>-TAMRA-3â (probe), 5â-<named-content content-type="sequence">CCTGAGCGCAAGTACTCTGTGT</named-content>-3â (forward primer), 5â-<named-content content-type="sequence">CTGCTTGCTGATCCACATCTG</named-content>-3â (reverse primer); <italic>Igf1</italic>: 5â- /56-FAM/TCCGGAAGC/ZEN/<named-content content-type="sequence">AACACTCACATCCACAA</named-content>/3IABkFQ/â3â (probe), 5â- <named-content content-type="sequence">AGTACATCTCCAGTCTCCTCA</named-content>-3â (forward primer), 5â- <named-content content-type="sequence">ATGCTCTTCAGTTCGTGTGT</named-content>-3â (reverse primer).</p></sec><sec id="s4-10"><title>Quantification and statistical analysis</title><p>All data are shown as mean Â± s.e.m. Statistical significance was determined using the unpaired t-test, two-way ANOVA with post hoc Tukeyâs multiple comparison test or one-way ANOVA with post hoc Tukeyâs multiple comparison test using GraphPad Prism 7 software. Differences were considered significant at p&lt;0.05.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Funding acquisition, Investigation, Visualization, Writing â original draft, Writing â review and editing</p></fn><fn fn-type="con" id="con2"><p>Investigation</p></fn><fn fn-type="con" id="con3"><p>Investigation</p></fn><fn fn-type="con" id="con4"><p>Supervision, Funding acquisition</p></fn><fn fn-type="con" id="con5"><p>Conceptualization, Supervision, Funding acquisition, Writing â original draft, Project administration, Writing â review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>All animal experiments were conducted according to relevant national and international guidelines contained in the 'Act on Welfare and Management of Animals' (Ministry of Environment of Japan) and 'Regulation of Laboratory Animals' (Kyushu University) and under the protocols approved by the Institutional Animal Care and Use committee review panels at Kyushu University (A24-305-1, A24-466-0).</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-105087-mdarchecklist1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting files.</p></sec><ack id="ack"><title>Acknowledgements</title><p>We would like to thank Editage for editing a draft of this manuscript. This work was supported by Japan Society for the Promotion of Science (JSPS) KAKENHI Grants JP19H05658 (MT), JP20H05900 (MT) and JP24H00067 (MT), by the Core Research for Evolutional Science and Technology (CREST) program from AMED under Grant Number 25gm1510013h (MT) by Research Support Project for Life Science and Drug Discovery (Basis for Supporting Innovative Drug Discovery and Life Science Research (BINDS)) from AMED under Grant Number JP25ama121031 (MT). TM was supported by AMED (JP20gm6310016, JP21wm0425001, JP23gm1910004, JP23jf0126004, 24zf0127012), JSPS (KAKENHI JP21H02752, JP22H05062, JP25H01009), The Mitsubishi Foundation, Daiichi Sankyo Foundation of Life Science, Mochida Memorial Foundation for Medical and Pharmaceutical Research, Astellas Foundation for Research on Metabolic disorders, Ono Pharmaceutical Foundation for Oncology, Immunology and Neurology, The Nakajima Foundation, The Uehara Memorial Foundation and Takeda Science Foundation. KK was supported by JSPS (KAKENHI JP23K19403, JP24K18621), JST (ACT-X Grant Number JPMJAX232B), Chugai Foundation for Innovative Drug Discovery Science, and The Ichiro Kanehara Foundation. This work was supported in part by the MEXT Cooperative Research Project Program, Medical Research Center Initiative for High Depth Omics, and CURE:JPMXP1323015486 for MIB, Kyushu University.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Butovsky</surname><given-names>O</given-names></name><name><surname>Talpalar</surname><given-names>AE</given-names></name><name><surname>Ben-Yaakov</surname><given-names>K</given-names></name><name><surname>Schwartz</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Activation of microglia by aggregated beta-amyloid or lipopolysaccharide impairs MHC-II expression and renders them cytotoxic whereas IFN-gamma and IL-4 render them protective</article-title><source>Molecular and Cellular Neurosciences</source><volume>29</volume><fpage>381</fpage><lpage>393</lpage><pub-id pub-id-type="doi">10.1016/j.mcn.2005.03.005</pub-id><pub-id pub-id-type="pmid">15890528</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Butovsky</surname><given-names>O</given-names></name><name><surname>Koronyo-Hamaoui</surname><given-names>M</given-names></name><name><surname>Kunis</surname><given-names>G</given-names></name><name><surname>Ophir</surname><given-names>E</given-names></name><name><surname>Landa</surname><given-names>G</given-names></name><name><surname>Cohen</surname><given-names>H</given-names></name><name><surname>Schwartz</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Glatiramer acetate fights against Alzheimerâs disease by inducing dendritic-like microglia expressing insulin-like growth factor 1</article-title><source>PNAS</source><volume>103</volume><fpage>11784</fpage><lpage>11789</lpage><pub-id pub-id-type="doi">10.1073/pnas.0604681103</pub-id><pub-id pub-id-type="pmid">16864778</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Butovsky</surname><given-names>O</given-names></name><name><surname>Jedrychowski</surname><given-names>MP</given-names></name><name><surname>Moore</surname><given-names>CS</given-names></name><name><surname>Cialic</surname><given-names>R</given-names></name><name><surname>Lanser</surname><given-names>AJ</given-names></name><name><surname>Gabriely</surname><given-names>G</given-names></name><name><surname>Koeglsperger</surname><given-names>T</given-names></name><name><surname>Dake</surname><given-names>B</given-names></name><name><surname>Wu</surname><given-names>PM</given-names></name><name><surname>Doykan</surname><given-names>CE</given-names></name><name><surname>Fanek</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Rothstein</surname><given-names>JD</given-names></name><name><surname>Ransohoff</surname><given-names>RM</given-names></name><name><surname>Gygi</surname><given-names>SP</given-names></name><name><surname>Antel</surname><given-names>JP</given-names></name><name><surname>Weiner</surname><given-names>HL</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Identification of a unique TGF-Î²-dependent molecular and functional signature in microglia</article-title><source>Nature Neuroscience</source><volume>17</volume><fpage>131</fpage><lpage>143</lpage><pub-id pub-id-type="doi">10.1038/nn.3599</pub-id><pub-id pub-id-type="pmid">24316888</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Celik</surname><given-names>MÃ</given-names></name><name><surname>Labuz</surname><given-names>D</given-names></name><name><surname>Keye</surname><given-names>J</given-names></name><name><surname>Glauben</surname><given-names>R</given-names></name><name><surname>Machelska</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>IL-4 induces M2 macrophages to produce sustained analgesia via opioids</article-title><source>JCI Insight</source><volume>5</volume><elocation-id>e133093</elocation-id><pub-id pub-id-type="doi">10.1172/jci.insight.133093</pub-id><pub-id pub-id-type="pmid">32102987</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaplan</surname><given-names>SR</given-names></name><name><surname>Bach</surname><given-names>FW</given-names></name><name><surname>Pogrel</surname><given-names>JW</given-names></name><name><surname>Chung</surname><given-names>JM</given-names></name><name><surname>Yaksh</surname><given-names>TL</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Quantitative assessment of tactile allodynia in the rat paw</article-title><source>Journal of Neuroscience Methods</source><volume>53</volume><fpage>55</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1016/0165-0270(94)90144-9</pub-id><pub-id pub-id-type="pmid">7990513</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiu</surname><given-names>IM</given-names></name><name><surname>Chen</surname><given-names>A</given-names></name><name><surname>Zheng</surname><given-names>Y</given-names></name><name><surname>Kosaras</surname><given-names>B</given-names></name><name><surname>Tsiftsoglou</surname><given-names>SA</given-names></name><name><surname>Vartanian</surname><given-names>TK</given-names></name><name><surname>Brown</surname><given-names>RH</given-names><suffix>Jr</suffix></name><name><surname>Carroll</surname><given-names>MC</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>T lymphocytes potentiate endogenous neuroprotective inflammation in a mouse model of ALS</article-title><source>PNAS</source><volume>105</volume><fpage>17913</fpage><lpage>17918</lpage><pub-id pub-id-type="doi">10.1073/pnas.0804610105</pub-id><pub-id pub-id-type="pmid">18997009</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cichon</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Spared nerve injury model of neuropathic pain in mice</article-title><source>Bio-Protocol</source><volume>8</volume><elocation-id>e2777</elocation-id><pub-id pub-id-type="doi">10.21769/bioprotoc.2777</pub-id><pub-id pub-id-type="pmid">29682596</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colloca</surname><given-names>L</given-names></name><name><surname>Ludman</surname><given-names>T</given-names></name><name><surname>Bouhassira</surname><given-names>D</given-names></name><name><surname>Baron</surname><given-names>R</given-names></name><name><surname>Dickenson</surname><given-names>AH</given-names></name><name><surname>Yarnitsky</surname><given-names>D</given-names></name><name><surname>Freeman</surname><given-names>R</given-names></name><name><surname>Truini</surname><given-names>A</given-names></name><name><surname>Attal</surname><given-names>N</given-names></name><name><surname>Finnerup</surname><given-names>NB</given-names></name><name><surname>Eccleston</surname><given-names>C</given-names></name><name><surname>Kalso</surname><given-names>E</given-names></name><name><surname>Bennett</surname><given-names>DL</given-names></name><name><surname>Dworkin</surname><given-names>RH</given-names></name><name><surname>Raja</surname><given-names>SN</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Neuropathic pain</article-title><source>Nature Reviews. Disease Primers</source><volume>3</volume><elocation-id>17002</elocation-id><pub-id pub-id-type="doi">10.1038/nrdp.2017.2</pub-id><pub-id pub-id-type="pmid">28205574</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coull</surname><given-names>JAM</given-names></name><name><surname>Beggs</surname><given-names>S</given-names></name><name><surname>Boudreau</surname><given-names>D</given-names></name><name><surname>Boivin</surname><given-names>D</given-names></name><name><surname>Tsuda</surname><given-names>M</given-names></name><name><surname>Inoue</surname><given-names>K</given-names></name><name><surname>Gravel</surname><given-names>C</given-names></name><name><surname>Salter</surname><given-names>MW</given-names></name><name><surname>De Koninck</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>BDNF from microglia causes the shift in neuronal anion gradient underlying neuropathic pain</article-title><source>Nature</source><volume>438</volume><fpage>1017</fpage><lpage>1021</lpage><pub-id pub-id-type="doi">10.1038/nature04223</pub-id><pub-id pub-id-type="pmid">16355225</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cunha</surname><given-names>FQ</given-names></name><name><surname>Poole</surname><given-names>S</given-names></name><name><surname>Lorenzetti</surname><given-names>BB</given-names></name><name><surname>Veiga</surname><given-names>FH</given-names></name><name><surname>Ferreira</surname><given-names>SH</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Cytokine-mediated inflammatory hyperalgesia limited by interleukin-4</article-title><source>British Journal of Pharmacology</source><volume>126</volume><fpage>45</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1038/sj.bjp.0702266</pub-id><pub-id pub-id-type="pmid">10051119</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Decosterd</surname><given-names>I</given-names></name><name><surname>Woolf</surname><given-names>CJ</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Spared nerve injury: an animal model of persistent peripheral neuropathic pain</article-title><source>Pain</source><volume>87</volume><fpage>149</fpage><lpage>158</lpage><pub-id pub-id-type="doi">10.1016/S0304-3959(00)00276-1</pub-id><pub-id pub-id-type="pmid">10924808</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>CY</given-names></name><name><surname>McAllister</surname><given-names>BB</given-names></name><name><surname>Stokes-Heck</surname><given-names>S</given-names></name><name><surname>Harding</surname><given-names>EK</given-names></name><name><surname>Pereira de Vasconcelos</surname><given-names>A</given-names></name><name><surname>Mah</surname><given-names>LK</given-names></name><name><surname>Lima</surname><given-names>LV</given-names></name><name><surname>van den Hoogen</surname><given-names>NJ</given-names></name><name><surname>Rosen</surname><given-names>SF</given-names></name><name><surname>Ham</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Zemp</surname><given-names>FJ</given-names></name><name><surname>Burkhard</surname><given-names>R</given-names></name><name><surname>Geuking</surname><given-names>MB</given-names></name><name><surname>Mahoney</surname><given-names>DJ</given-names></name><name><surname>Zamponi</surname><given-names>GW</given-names></name><name><surname>Mogil</surname><given-names>JS</given-names></name><name><surname>Ousman</surname><given-names>SS</given-names></name><name><surname>Trang</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2025">2025</year><article-title>Divergent sex-specific pannexin-1 mechanisms in microglia and T cells underlie neuropathic pain</article-title><source>Neuron</source><volume>113</volume><fpage>896</fpage><lpage>911</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2025.01.005</pub-id><pub-id pub-id-type="pmid">39892387</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finnerup</surname><given-names>NB</given-names></name><name><surname>Kuner</surname><given-names>R</given-names></name><name><surname>Jensen</surname><given-names>TS</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Neuropathic pain: from mechanisms to treatment</article-title><source>Physiological Reviews</source><volume>101</volume><fpage>259</fpage><lpage>301</lpage><pub-id pub-id-type="doi">10.1152/physrev.00045.2019</pub-id><pub-id pub-id-type="pmid">32584191</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grace</surname><given-names>PM</given-names></name><name><surname>Hutchinson</surname><given-names>MR</given-names></name><name><surname>Maier</surname><given-names>SF</given-names></name><name><surname>Watkins</surname><given-names>LR</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Pathological pain and the neuroimmune interface</article-title><source>Nature Reviews. Immunology</source><volume>14</volume><fpage>217</fpage><lpage>231</lpage><pub-id pub-id-type="doi">10.1038/nri3621</pub-id><pub-id pub-id-type="pmid">24577438</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hao</surname><given-names>S</given-names></name><name><surname>Mata</surname><given-names>M</given-names></name><name><surname>Glorioso</surname><given-names>JC</given-names></name><name><surname>Fink</surname><given-names>DJ</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>HSV-mediated expression of interleukin-4 in dorsal root ganglion neurons reduces neuropathic pain</article-title><source>Molecular Pain</source><volume>2</volume><elocation-id>6</elocation-id><pub-id pub-id-type="doi">10.1186/1744-8069-2-6</pub-id><pub-id pub-id-type="pmid">16503976</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ho Kim</surname><given-names>S</given-names></name><name><surname>Mo Chung</surname><given-names>J</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat</article-title><source>Pain</source><volume>50</volume><fpage>355</fpage><lpage>363</lpage><pub-id pub-id-type="doi">10.1016/0304-3959(92)90041-9</pub-id><pub-id pub-id-type="pmid">1333581</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hylden</surname><given-names>JL</given-names></name><name><surname>Wilcox</surname><given-names>GL</given-names></name></person-group><year iso-8601-date="1980">1980</year><article-title>Intrathecal morphine in mice: a new technique</article-title><source>European Journal of Pharmacology</source><volume>67</volume><fpage>313</fpage><lpage>316</lpage><pub-id pub-id-type="doi">10.1016/0014-2999(80)90515-4</pub-id><pub-id pub-id-type="pmid">6893963</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inoue</surname><given-names>K</given-names></name><name><surname>Tsuda</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Microglia in neuropathic pain: cellular and molecular mechanisms and therapeutic potential</article-title><source>Nature Reviews. Neuroscience</source><volume>19</volume><fpage>138</fpage><lpage>152</lpage><pub-id pub-id-type="doi">10.1038/nrn.2018.2</pub-id><pub-id pub-id-type="pmid">29416128</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ito</surname><given-names>D</given-names></name><name><surname>Imai</surname><given-names>Y</given-names></name><name><surname>Ohsawa</surname><given-names>K</given-names></name><name><surname>Nakajima</surname><given-names>K</given-names></name><name><surname>Fukuuchi</surname><given-names>Y</given-names></name><name><surname>Kohsaka</surname><given-names>S</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Microglia-specific localisation of a novel calcium binding protein, Iba1</article-title><source>Brain Research. Molecular Brain Research</source><volume>57</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/s0169-328x(98)00040-0</pub-id><pub-id pub-id-type="pmid">9630473</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ji</surname><given-names>RR</given-names></name><name><surname>Chamessian</surname><given-names>A</given-names></name><name><surname>Zhang</surname><given-names>YQ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Pain regulation by non-neuronal cells and inflammation</article-title><source>Science</source><volume>354</volume><fpage>572</fpage><lpage>577</lpage><pub-id pub-id-type="doi">10.1126/science.aaf8924</pub-id><pub-id pub-id-type="pmid">27811267</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ji</surname><given-names>RR</given-names></name><name><surname>Donnelly</surname><given-names>CR</given-names></name><name><surname>Nedergaard</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Astrocytes in chronic pain and itch</article-title><source>Nature Reviews. Neuroscience</source><volume>20</volume><fpage>667</fpage><lpage>685</lpage><pub-id pub-id-type="doi">10.1038/s41583-019-0218-1</pub-id><pub-id pub-id-type="pmid">31537912</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jung</surname><given-names>S</given-names></name><name><surname>Unutmaz</surname><given-names>D</given-names></name><name><surname>Wong</surname><given-names>P</given-names></name><name><surname>Sano</surname><given-names>G-I</given-names></name><name><surname>De los Santos</surname><given-names>K</given-names></name><name><surname>Sparwasser</surname><given-names>T</given-names></name><name><surname>Wu</surname><given-names>S</given-names></name><name><surname>Vuthoori</surname><given-names>S</given-names></name><name><surname>Ko</surname><given-names>K</given-names></name><name><surname>Zavala</surname><given-names>F</given-names></name><name><surname>Pamer</surname><given-names>EG</given-names></name><name><surname>Littman</surname><given-names>DR</given-names></name><name><surname>Lang</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>In vivo depletion of CD11c+ dendritic cells abrogates priming of CD8+ T cells by exogenous cell-associated antigens</article-title><source>Immunity</source><volume>17</volume><fpage>211</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.1016/s1074-7613(02)00365-5</pub-id><pub-id pub-id-type="pmid">12196292</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keren-Shaul</surname><given-names>H</given-names></name><name><surname>Spinrad</surname><given-names>A</given-names></name><name><surname>Weiner</surname><given-names>A</given-names></name><name><surname>Matcovitch-Natan</surname><given-names>O</given-names></name><name><surname>Dvir-Szternfeld</surname><given-names>R</given-names></name><name><surname>Ulland</surname><given-names>TK</given-names></name><name><surname>David</surname><given-names>E</given-names></name><name><surname>Baruch</surname><given-names>K</given-names></name><name><surname>Lara-Astaiso</surname><given-names>D</given-names></name><name><surname>Toth</surname><given-names>B</given-names></name><name><surname>Itzkovitz</surname><given-names>S</given-names></name><name><surname>Colonna</surname><given-names>M</given-names></name><name><surname>Schwartz</surname><given-names>M</given-names></name><name><surname>Amit</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>A unique microglia type associated with restricting development of alzheimerâs disease</article-title><source>Cell</source><volume>169</volume><fpage>1276</fpage><lpage>1290</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.05.018</pub-id><pub-id pub-id-type="pmid">28602351</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kiguchi</surname><given-names>N</given-names></name><name><surname>Kobayashi</surname><given-names>Y</given-names></name><name><surname>Saika</surname><given-names>F</given-names></name><name><surname>Sakaguchi</surname><given-names>H</given-names></name><name><surname>Maeda</surname><given-names>T</given-names></name><name><surname>Kishioka</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Peripheral interleukin-4 ameliorates inflammatory macrophage-dependent neuropathic pain</article-title><source>Pain</source><volume>156</volume><fpage>684</fpage><lpage>693</lpage><pub-id pub-id-type="doi">10.1097/j.pain.0000000000000097</pub-id><pub-id pub-id-type="pmid">25630024</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kohno</surname><given-names>K</given-names></name><name><surname>Kitano</surname><given-names>J</given-names></name><name><surname>Kohro</surname><given-names>Y</given-names></name><name><surname>Tozaki-Saitoh</surname><given-names>H</given-names></name><name><surname>Inoue</surname><given-names>K</given-names></name><name><surname>Tsuda</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Temporal kinetics of microgliosis in the spinal dorsal horn after peripheral nerve injury in rodents</article-title><source>Biological &amp; Pharmaceutical Bulletin</source><volume>41</volume><fpage>1096</fpage><lpage>1102</lpage><pub-id pub-id-type="doi">10.1248/bpb.b18-00278</pub-id><pub-id pub-id-type="pmid">29962405</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kohno</surname><given-names>K</given-names></name><name><surname>Shirasaka</surname><given-names>R</given-names></name><name><surname>Yoshihara</surname><given-names>K</given-names></name><name><surname>Mikuriya</surname><given-names>S</given-names></name><name><surname>Tanaka</surname><given-names>K</given-names></name><name><surname>Takanami</surname><given-names>K</given-names></name><name><surname>Inoue</surname><given-names>K</given-names></name><name><surname>Sakamoto</surname><given-names>H</given-names></name><name><surname>Ohkawa</surname><given-names>Y</given-names></name><name><surname>Masuda</surname><given-names>T</given-names></name><name><surname>Tsuda</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>A spinal microglia population involved in remitting and relapsing neuropathic pain</article-title><source>Science</source><volume>376</volume><fpage>86</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1126/science.abf6805</pub-id><pub-id pub-id-type="pmid">35357926</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuhn</surname><given-names>JA</given-names></name><name><surname>Vainchtein</surname><given-names>ID</given-names></name><name><surname>Braz</surname><given-names>J</given-names></name><name><surname>Hamel</surname><given-names>K</given-names></name><name><surname>Bernstein</surname><given-names>M</given-names></name><name><surname>Craik</surname><given-names>V</given-names></name><name><surname>Dahlgren</surname><given-names>MW</given-names></name><name><surname>Ortiz-Carpena</surname><given-names>J</given-names></name><name><surname>Molofsky</surname><given-names>AB</given-names></name><name><surname>Molofsky</surname><given-names>AV</given-names></name><name><surname>Basbaum</surname><given-names>AI</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Regulatory T-cells inhibit microglia-induced pain hypersensitivity in female mice</article-title><source>eLife</source><volume>10</volume><elocation-id>e69056</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.69056</pub-id><pub-id pub-id-type="pmid">34652270</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Labuz</surname><given-names>D</given-names></name><name><surname>Celik</surname><given-names>MÃ</given-names></name><name><surname>Seitz</surname><given-names>V</given-names></name><name><surname>Machelska</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Interleukin-4 induces the release of opioid peptides from M1 macrophages in pathological pain</article-title><source>The Journal of Neuroscience</source><volume>41</volume><fpage>2870</fpage><lpage>2882</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.3040-20.2021</pub-id><pub-id pub-id-type="pmid">33593854</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lindquist</surname><given-names>RL</given-names></name><name><surname>Shakhar</surname><given-names>G</given-names></name><name><surname>Dudziak</surname><given-names>D</given-names></name><name><surname>Wardemann</surname><given-names>H</given-names></name><name><surname>Eisenreich</surname><given-names>T</given-names></name><name><surname>Dustin</surname><given-names>ML</given-names></name><name><surname>Nussenzweig</surname><given-names>MC</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Visualizing dendritic cell networks in vivo</article-title><source>Nature Immunology</source><volume>5</volume><fpage>1243</fpage><lpage>1250</lpage><pub-id pub-id-type="doi">10.1038/ni1139</pub-id><pub-id pub-id-type="pmid">15543150</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>JL</given-names></name><name><surname>Grinberg</surname><given-names>A</given-names></name><name><surname>Westphal</surname><given-names>H</given-names></name><name><surname>Sauer</surname><given-names>B</given-names></name><name><surname>Accili</surname><given-names>D</given-names></name><name><surname>Karas</surname><given-names>M</given-names></name><name><surname>LeRoith</surname><given-names>D</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Insulin-like growth factor-I affects perinatal lethality and postnatal development in a gene dosage-dependent manner: manipulation using the Cre/loxP system in transgenic mice</article-title><source>Molecular Endocrinology</source><volume>12</volume><fpage>1452</fpage><lpage>1462</lpage><pub-id pub-id-type="doi">10.1210/mend.12.9.0162</pub-id><pub-id pub-id-type="pmid">9731712</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masuda</surname><given-names>T</given-names></name><name><surname>Tsuda</surname><given-names>M</given-names></name><name><surname>Yoshinaga</surname><given-names>R</given-names></name><name><surname>Tozaki-Saitoh</surname><given-names>H</given-names></name><name><surname>Ozato</surname><given-names>K</given-names></name><name><surname>Tamura</surname><given-names>T</given-names></name><name><surname>Inoue</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>IRF8 is a critical transcription factor for transforming microglia into a reactive phenotype</article-title><source>Cell Reports</source><volume>1</volume><fpage>334</fpage><lpage>340</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2012.02.014</pub-id><pub-id pub-id-type="pmid">22832225</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masuda</surname><given-names>T</given-names></name><name><surname>Iwamoto</surname><given-names>S</given-names></name><name><surname>Yoshinaga</surname><given-names>R</given-names></name><name><surname>Tozaki-Saitoh</surname><given-names>H</given-names></name><name><surname>Nishiyama</surname><given-names>A</given-names></name><name><surname>Mak</surname><given-names>TW</given-names></name><name><surname>Tamura</surname><given-names>T</given-names></name><name><surname>Tsuda</surname><given-names>M</given-names></name><name><surname>Inoue</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Transcription factor IRF5 drives P2X4R+-reactive microglia gating neuropathic pain</article-title><source>Nature Communications</source><volume>5</volume><elocation-id>3771</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms4771</pub-id><pub-id pub-id-type="pmid">24818655</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masuda</surname><given-names>T</given-names></name><name><surname>Kohro</surname><given-names>Y</given-names></name><name><surname>Inoue</surname><given-names>K</given-names></name><name><surname>Tsuda</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Peripheral nerve injury: a mouse model of neuropathic pain</article-title><source>Bio-Protocol</source><volume>7</volume><elocation-id>e2252</elocation-id><pub-id pub-id-type="doi">10.21769/BioProtoc.2252</pub-id><pub-id pub-id-type="pmid">34541241</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Midavaine</surname><given-names>Ã</given-names></name><name><surname>Moraes</surname><given-names>BC</given-names></name><name><surname>Benitez</surname><given-names>J</given-names></name><name><surname>Rodriguez</surname><given-names>SR</given-names></name><name><surname>Braz</surname><given-names>JM</given-names></name><name><surname>Kochhar</surname><given-names>NP</given-names></name><name><surname>Eckalbar</surname><given-names>WL</given-names></name><name><surname>Tian</surname><given-names>L</given-names></name><name><surname>Domingos</surname><given-names>AI</given-names></name><name><surname>Pintar</surname><given-names>JE</given-names></name><name><surname>Basbaum</surname><given-names>AI</given-names></name><name><surname>Kashem</surname><given-names>SW</given-names></name></person-group><year iso-8601-date="2025">2025</year><article-title>Meningeal regulatory T cells inhibit nociception in female mice</article-title><source>Science</source><volume>388</volume><fpage>96</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.1126/science.adq6531</pub-id><pub-id pub-id-type="pmid">40179196</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nie</surname><given-names>B</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Bai</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Huang</surname><given-names>Z</given-names></name><name><surname>Xie</surname><given-names>M</given-names></name><name><surname>Xu</surname><given-names>T</given-names></name><name><surname>Xin</surname><given-names>W</given-names></name><name><surname>Zeng</surname><given-names>W</given-names></name><name><surname>Ouyang</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>AKAP150 involved in paclitaxel-induced neuropathic pain via inhibiting CN/NFAT2 pathway and downregulating IL-4</article-title><source>Brain, Behavior, and Immunity</source><volume>68</volume><fpage>158</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.1016/j.bbi.2017.10.015</pub-id><pub-id pub-id-type="pmid">29056557</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niehaus</surname><given-names>JK</given-names></name><name><surname>Taylor-Blake</surname><given-names>B</given-names></name><name><surname>Loo</surname><given-names>L</given-names></name><name><surname>Simon</surname><given-names>JM</given-names></name><name><surname>Zylka</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Spinal macrophages resolve nociceptive hypersensitivity after peripheral injury</article-title><source>Neuron</source><volume>109</volume><fpage>1274</fpage><lpage>1282</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2021.02.018</pub-id><pub-id pub-id-type="pmid">33667343</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okutani</surname><given-names>H</given-names></name><name><surname>Yamanaka</surname><given-names>H</given-names></name><name><surname>Kobayashi</surname><given-names>K</given-names></name><name><surname>Okubo</surname><given-names>M</given-names></name><name><surname>Noguchi</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Recombinant interleukin-4 alleviates mechanical allodynia via injury-induced interleukin-4 receptor alpha in spinal microglia in a rat model of neuropathic pain</article-title><source>Glia</source><volume>66</volume><fpage>1775</fpage><lpage>1787</lpage><pub-id pub-id-type="doi">10.1002/glia.23340</pub-id><pub-id pub-id-type="pmid">29693281</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parkhurst</surname><given-names>CN</given-names></name><name><surname>Yang</surname><given-names>G</given-names></name><name><surname>Ninan</surname><given-names>I</given-names></name><name><surname>Savas</surname><given-names>JN</given-names></name><name><surname>Yates</surname><given-names>JR</given-names><suffix>III</suffix></name><name><surname>Lafaille</surname><given-names>JJ</given-names></name><name><surname>Hempstead</surname><given-names>BL</given-names></name><name><surname>Littman</surname><given-names>DR</given-names></name><name><surname>Gan</surname><given-names>WB</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Microglia promote learning-dependent synapse formation through brain-derived neurotrophic factor</article-title><source>Cell</source><volume>155</volume><fpage>1596</fpage><lpage>1609</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2013.11.030</pub-id><pub-id pub-id-type="pmid">24360280</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>J</given-names></name><name><surname>Gu</surname><given-names>N</given-names></name><name><surname>Zhou</surname><given-names>L</given-names></name><name><surname>B Eyo</surname><given-names>U</given-names></name><name><surname>Murugan</surname><given-names>M</given-names></name><name><surname>Gan</surname><given-names>WB</given-names></name><name><surname>Wu</surname><given-names>LJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Microglia and monocytes synergistically promote the transition from acute to chronic pain after nerve injury</article-title><source>Nature Communications</source><volume>7</volume><elocation-id>12029</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms12029</pub-id><pub-id pub-id-type="pmid">27349690</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rigaud</surname><given-names>M</given-names></name><name><surname>Gemes</surname><given-names>G</given-names></name><name><surname>Barabas</surname><given-names>ME</given-names></name><name><surname>Chernoff</surname><given-names>DI</given-names></name><name><surname>Abram</surname><given-names>SE</given-names></name><name><surname>Stucky</surname><given-names>CL</given-names></name><name><surname>Hogan</surname><given-names>QH</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Species and strain differences in rodent sciatic nerve anatomy: implications for studies of neuropathic pain</article-title><source>Pain</source><volume>136</volume><fpage>188</fpage><lpage>201</lpage><pub-id pub-id-type="doi">10.1016/j.pain.2008.01.016</pub-id><pub-id pub-id-type="pmid">18316160</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shibata</surname><given-names>Y</given-names></name><name><surname>Matsumoto</surname><given-names>Y</given-names></name><name><surname>Kohno</surname><given-names>K</given-names></name><name><surname>Nakashima</surname><given-names>Y</given-names></name><name><surname>Tsuda</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2025">2025</year><article-title>Microgliosis in the spinal dorsal horn early after peripheral nerve injury is associated with damage to primary afferent AÎ²-fibers</article-title><source>Cells</source><volume>14</volume><elocation-id>666</elocation-id><pub-id pub-id-type="doi">10.3390/cells14090666</pub-id><pub-id pub-id-type="pmid">40358190</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sideris-Lampretsas</surname><given-names>G</given-names></name><name><surname>Malcangio</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Pain-resolving microglia</article-title><source>Science</source><volume>376</volume><fpage>33</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1126/science.abo5592</pub-id><pub-id pub-id-type="pmid">35357920</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tansley</surname><given-names>S</given-names></name><name><surname>Uttam</surname><given-names>S</given-names></name><name><surname>UreÃ±a GuzmÃ¡n</surname><given-names>A</given-names></name><name><surname>Yaqubi</surname><given-names>M</given-names></name><name><surname>Pacis</surname><given-names>A</given-names></name><name><surname>Parisien</surname><given-names>M</given-names></name><name><surname>Deamond</surname><given-names>H</given-names></name><name><surname>Wong</surname><given-names>C</given-names></name><name><surname>Rabau</surname><given-names>O</given-names></name><name><surname>Brown</surname><given-names>N</given-names></name><name><surname>Haglund</surname><given-names>L</given-names></name><name><surname>Ouellet</surname><given-names>J</given-names></name><name><surname>Santaguida</surname><given-names>C</given-names></name><name><surname>Ribeiro-da-Silva</surname><given-names>A</given-names></name><name><surname>Tahmasebi</surname><given-names>S</given-names></name><name><surname>Prager-Khoutorsky</surname><given-names>M</given-names></name><name><surname>Ragoussis</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Salter</surname><given-names>MW</given-names></name><name><surname>Diatchenko</surname><given-names>L</given-names></name><name><surname>Healy</surname><given-names>LM</given-names></name><name><surname>Mogil</surname><given-names>JS</given-names></name><name><surname>Khoutorsky</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Single-cell RNA sequencing reveals time- and sex-specific responses of mouse spinal cord microglia to peripheral nerve injury and links ApoE to chronic pain</article-title><source>Nature Communications</source><volume>13</volume><elocation-id>843</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-022-28473-8</pub-id><pub-id pub-id-type="pmid">35149686</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsuda</surname><given-names>M</given-names></name><name><surname>Shigemoto-Mogami</surname><given-names>Y</given-names></name><name><surname>Koizumi</surname><given-names>S</given-names></name><name><surname>Mizokoshi</surname><given-names>A</given-names></name><name><surname>Kohsaka</surname><given-names>S</given-names></name><name><surname>Salter</surname><given-names>MW</given-names></name><name><surname>Inoue</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>P2X4 receptors induced in spinal microglia gate tactile allodynia after nerve injury</article-title><source>Nature</source><volume>424</volume><fpage>778</fpage><lpage>783</lpage><pub-id pub-id-type="doi">10.1038/nature01786</pub-id><pub-id pub-id-type="pmid">12917686</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsuda</surname><given-names>M</given-names></name><name><surname>Masuda</surname><given-names>T</given-names></name><name><surname>Kohno</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Microglial diversity in neuropathic pain</article-title><source>Trends in Neurosciences</source><volume>46</volume><fpage>597</fpage><lpage>610</lpage><pub-id pub-id-type="doi">10.1016/j.tins.2023.05.001</pub-id><pub-id pub-id-type="pmid">37244781</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vale</surname><given-names>ML</given-names></name><name><surname>Marques</surname><given-names>JB</given-names></name><name><surname>Moreira</surname><given-names>CA</given-names></name><name><surname>Rocha</surname><given-names>FAC</given-names></name><name><surname>Ferreira</surname><given-names>SH</given-names></name><name><surname>Poole</surname><given-names>S</given-names></name><name><surname>Cunha</surname><given-names>FQ</given-names></name><name><surname>Ribeiro</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Antinociceptive effects of interleukin-4, -10, and -13 on the writhing response in mice and zymosan-induced knee joint incapacitation in rats</article-title><source>The Journal of Pharmacology and Experimental Therapeutics</source><volume>304</volume><fpage>102</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.1124/jpet.102.038703</pub-id><pub-id pub-id-type="pmid">12490580</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vanderwall</surname><given-names>AG</given-names></name><name><surname>Milligan</surname><given-names>ED</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Cytokines in pain: harnessing endogenous anti-inflammatory signaling for improved pain management</article-title><source>Frontiers in Immunology</source><volume>10</volume><elocation-id>3009</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2019.03009</pub-id><pub-id pub-id-type="pmid">31921220</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wlodarczyk</surname><given-names>A</given-names></name><name><surname>Benmamar-Badel</surname><given-names>A</given-names></name><name><surname>CÃ©dile</surname><given-names>O</given-names></name><name><surname>Jensen</surname><given-names>KN</given-names></name><name><surname>Kramer</surname><given-names>I</given-names></name><name><surname>Elsborg</surname><given-names>NB</given-names></name><name><surname>Owens</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>CSF1R stimulation promotes increased neuroprotection by CD11c+ microglia in EAE</article-title><source>Frontiers in Cellular Neuroscience</source><volume>12</volume><elocation-id>523</elocation-id><pub-id pub-id-type="doi">10.3389/fncel.2018.00523</pub-id><pub-id pub-id-type="pmid">30687013</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>YU</given-names></name><name><surname>Zhao</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Bosco</surname><given-names>DB</given-names></name><name><surname>Pang</surname><given-names>Y-P</given-names></name><name><surname>Zhong</surname><given-names>J</given-names></name><name><surname>Sheth</surname><given-names>U</given-names></name><name><surname>Martens</surname><given-names>YA</given-names></name><name><surname>Zhao</surname><given-names>N</given-names></name><name><surname>Liu</surname><given-names>C-C</given-names></name><name><surname>Zhuang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Dickson</surname><given-names>DW</given-names></name><name><surname>Mattson</surname><given-names>MP</given-names></name><name><surname>Bu</surname><given-names>G</given-names></name><name><surname>Wu</surname><given-names>L-J</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>TREM2 interacts with TDP-43 and mediates microglial neuroprotection against TDP-43-related neurodegeneration</article-title><source>Nature Neuroscience</source><volume>25</volume><fpage>26</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1038/s41593-021-00975-6</pub-id><pub-id pub-id-type="pmid">34916658</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.105087.3.sa0</article-id><title-group><article-title>eLife Assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Owoyele</surname><given-names>Bamidele</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/032kdwk38</institution-id><institution>University of Ilorin</institution></institution-wrap><country>Nigeria</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Convincing</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Important</kwd></kwd-group></front-stub><body><p>This study is <bold>important</bold> as it highlighted how IL-4 regulates the reactive state of a specific microglial population by increasing the proportion of CD11c+ microglial cells and ultimately suppressing neuropathic pain. The study employs a combination of behavioral assays, pharmacogenetic manipulation of microglial populations, and characterization of microglial markers to address these questions. It provided <bold>convincing</bold> evidence for the proposed mechanism of IL-4-mediated microglial regulation in neuropathic pain.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.105087.3.sa1</article-id><title-group><article-title>Reviewer #2 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>The authors aimed to investigate how IL-4 modulates the reactive state of microglia in the context of neuropathic pain. Specifically, they sought to determine whether IL-4 drives an increase in CD11c+ microglial cells, a population associated with anti-inflammatory responses, and whether this change is linked to the suppression of neuropathic pain. The study employs a combination of behavioral assays, pharmacogenetic manipulation of microglial populations, and characterization of microglial markers to address these questions.</p><p>Strengths:</p><p>Strengths: The methodological approach in this study is robust, providing convincing evidence for the proposed mechanism of IL-4-mediated microglial regulation in neuropathic pain. The experimental design is well thought out, utilizing two distinct neuropathic pain models (SpNT and SNI), each yielding different outcomes. The SpNT model demonstrates spontaneous pain remission and an increase in the CD11c+ microglial population, which correlates with pain suppression. In contrast, the SNI model, which does not show spontaneous pain remission, lacks a significant increase in CD11c+ microglia, underscoring the specificity of the observed phenomenon. This design effectively highlights the role of the CD11c+ microglial population in pain modulation. The use of behavioral tests provides a clear functional assessment of IL-4 manipulation, and pharmacogenetic tools allow for precise control of microglial populations, minimizing off-target effects. Notably, the manipulation targets the CD11c promoter, which presumably reduces the risk of non-specific ablation of other microglial populations, strengthening the experimental precision. Moreover, the thorough characterization of microglial markers adds depth to the analysis, ensuring that the changes in microglial populations are accurately linked to the behavioral outcomes.</p><p>Weaknesses:</p><p>One potential limitation of the study is that the mechanistic details of how IL-4 induces the observed shift in microglial populations are not fully explored. While the study demonstrates a correlation between IL-4 and CD11c+ microglial cells, a deeper investigation into the specific signaling pathways and molecular processes driving this population shift would greatly strengthen the conclusions. Additionally, the paper does not clearly integrate the findings into the broader context of microglial reactive state regulation in neuropathic pain.</p><p>Comments on revisions:</p><p>In the revised manuscript, the authors have successfully addressed my previous concerns as well as the other reviewers. I do not have further concerns about this study.</p></body></sub-article><sub-article article-type="author-comment" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.105087.3.sa2</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kohno</surname><given-names>Keita</given-names></name><role specific-use="author">Author</role><aff><institution>Kyushu University</institution><addr-line><named-content content-type="city">Fukuoka</named-content></addr-line><country>Japan</country></aff></contrib><contrib contrib-type="author"><name><surname>Shirasaka</surname><given-names>Ryoji</given-names></name><role specific-use="author">Author</role><aff><institution>Kyushu University</institution><addr-line><named-content content-type="city">Fukuoka</named-content></addr-line><country>Japan</country></aff></contrib><contrib contrib-type="author"><name><surname>Hirose</surname><given-names>Keita</given-names></name><role specific-use="author">Author</role><aff><institution>Kyushu University</institution><addr-line><named-content content-type="city">Fukuoka</named-content></addr-line><country>Japan</country></aff></contrib><contrib contrib-type="author"><name><surname>Masuda</surname><given-names>Takahiro</given-names></name><role specific-use="author">Author</role><aff><institution>Kyushu University</institution><addr-line><named-content content-type="city">Fukuoka</named-content></addr-line><country>Japan</country></aff></contrib><contrib contrib-type="author"><name><surname>Tsuda</surname><given-names>Makoto</given-names></name><role specific-use="author">Author</role><aff><institution>Kyushu University</institution><addr-line><named-content content-type="city">Fukuoka</named-content></addr-line><country>Japan</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authorsâ response to the original reviews.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #1 (Public review):</bold></p><p>Summary:</p><p>Kohno et al. examined whether the anti-inflammatory cytokine IL-4 attenuates neuropathic pain by promoting the emergence of antinociceptive microglia in the dorsal horn of the spinal cord. In two models of neuropathic pain following peripheral nerve injury, intrathecal administration of IL-4 once a day for 3 days from day 14 to day 17 after injury, attenuates hypersensitivity to mechanical stimuli in the hind paw ipsilateral to nerve injury. Such an antinociceptive effect correlates with a higher number of CD11c+microglia in the dorsal horn of the spinal cord which is the termination area for primary afferent fibres injured in the periphery. Interestingly, CD11c+ microglia emerge spontaneously in the dorsal horn in concomitance with the resolution of pain in the spinal nerve model of pain, but not in the spared nerve injury model where pain does not resolve, confirming that this cluster of microglia is involved in resolution pain.</p><p>Based on existing evidence that the receptor for IL-4, namely IL-4R, is expressed by microglia, the authors suggest that IL-4R mediates IL-4 effect in microglia including up-regulation of Igf1 mRNA. They have previously reported that IGF-1 can attenuate pain neuron activity in the spinal cord.</p><p>Strengths:</p><p>This study includes cutting-edge techniques such as flow cytometry analysis of microglia and transgenic mouse models.</p><p>Weaknesses:</p><p>The conclusion of this paper is supported by data, but the interpretation of some data requires clarification.</p></disp-quote><p>We appreciate the reviewer's careful reading of our paper. According to the reviewer's comments, we have performed new immunohistochemical experiments and added some discussion in the revised manuscript (please see the point-by-point responses below).</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Public review):</bold></p><p>Summary:</p><p>The authors aimed to investigate how IL-4 modulates the reactive state of microglia in the context of neuropathic pain. Specifically, they sought to determine whether IL-4 drives an increase in CD11c+ microglial cells, a population associated with anti-inflammatory responses and whether this change is linked to the suppression of neuropathic pain. The study employs a combination of behavioral assays, pharmacogenetic manipulation of microglial populations, and characterization of microglial markers to address these questions.</p><p>Strengths:</p><p>The methodological approach in this study is robust, providing convincing evidence for the proposed mechanism of IL-4-mediated microglial regulation in neuropathic pain. The experimental design is well thought out, utilizing two distinct neuropathic pain models (SpNT and SNI), each yielding different outcomes. The SpNT model demonstrates spontaneous pain remission and an increase in the CD11c+ microglial population, which correlates with pain suppression. In contrast, the SNI model, which does not show spontaneous pain remission, lacks a significant increase in CD11c+ microglia, underscoring the specificity of the observed phenomenon. This design effectively highlights the role of the CD11c+ microglial population in pain modulation. The use of behavioral tests provides a clear functional assessment of IL-4 manipulation, and pharmacogenetic tools allow for precise control of microglial populations, minimizing off-target effects. Notably, the manipulation targets the CD11c promoter, which presumably reduces the risk of non-specific ablation of other microglial populations, strengthening the experimental precision. Moreover, the thorough characterization of microglial markers adds depth to the analysis, ensuring that the changes in microglial populations are accurately linked to the behavioral outcomes.</p><p>Weaknesses:</p><p>One potential limitation of the study is that the mechanistic details of how IL-4 induces the observed shift in microglial populations are not fully explored. While the study demonstrates a correlation between IL-4 and CD11c+ microglial cells, a deeper investigation into the specific signaling pathways and molecular processes driving this population shift would greatly strengthen the conclusions. Additionally, the paper does not clearly integrate the findings into the broader context of microglial reactive state regulation in neuropathic pain.</p></disp-quote><p>We thank the reviewer for these insightful comments on our paper. As the reviewer's suggested, further investigation of the specific signaling pathways and molecular processes by which IL-4 induces a transition of spinal microglia to the CD11c+ state would strengthen our conclusion and also provide important clues to discovering new therapeutic targets. In revising the manuscript, we have included this in the Discussion section (line 264-267), and we hope that future studies clarify these points. As for the additional comment, we have added a brief summary of existing research on microglial function in neuropathic pain at the beginning of the Discussion section (line 188â196).</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #1 (Recommendations for the authors):</bold></p><p>The conclusions of this paper are supported by data, but the interpretation of some data requires clarification.</p><p>(1) In Figure 1D and Figure 7 C, CD11c+ microglia numbers are higher in contralateral dorsal horns after IL-4 administration despite IL-4 having no effect on pain thresholds. The authors should discuss these findings.</p></disp-quote><p>As the reviewer pointed out, IL-4 increased the number of CD11c<sup>+</sup> microglia in the contralateral spinal dorsal horn (SDH) but did not affect pain thresholds in the contralateral hindpaw. The data seem to be related to the selective effect of CD11c+ microglia and their factors (especially IGF1) on nerve injury-induced pain hypersensitivity. In fact, depletion of CD11c+ spinal microglia and intrathecal administration of IGF1 do not elevate pain threshold of the contralateral hindpaw (Science 376: 86â90, 2022). We have added above statement in the Discussion section (line 208â 213).</p><disp-quote content-type="editor-comment"><p>(2) Do monocytes infiltrate the dorsal horn and DRG after intrathecal injections?</p></disp-quote><p>To address this reviewer's comment, we performed new immunohistochemical experiments to analyze monocytes in the SDH using an antibody for CD169 (a marker for bone marrow-derived monocytes/macrophages, but not for resident microglia) (J Clin Invest 122: 3063â 3087, 2012; Cell Rep 3: 605â614, 2016) and found no CD169+ monocytes in the SDH parenchyma after SpNT. Consistent with this data, we have previously demonstrated that few bone marrow-derived monocytes/macrophages are recruited to the SDH after SpNT (Sci Rep 6: 23701, 2016). Similarly, no CD169+ monocytes in the SDH parenchyma were observed in SpNT mice treated intrathecally with PBS or IL-4 (Figure 1âfigure supplement 1A).</p><p>In the DRG, CD169 is constitutively expressed in macrophages. Thus, in accordance with a recent report showing that monocytes infiltrating the DRG are positive for chemokine (C-C motif) receptor 2 (CCR2) (J Exp Med 221: e20230675, 2024), we analyzed CCR2+ cells and found that CCR2+ IBA1dim monocytes were observed in the capsule and parenchyma of the DRG of naive mice (Figure 1âfigure supplement 1B). After SpNT, CCR2+ IBA1dim monocytes in the DRG parenchyma increased. Intrathecal treatment of IL-4 increased CCR2+ IBA1dim cells in the DRG capsule. However, the involvement of these monocytes in the DRG in IL-4-induced alleviation of neuropathic pain is unclear and warrants further investigation. In revising the manuscript, we have included additional data (Figure 1âfigure supplement 1) and corresponding text in the Results (line 112â114) and Discussion section (line 218â222).</p><disp-quote content-type="editor-comment"><p>(3) In Figure 4, depletion of CD11c+ cells in dorsal root ganglia (DRG) ameliorates neuropathic thresholds but does not alter the anti-nociceptive effect of IL-4 injected intrathecal. It appears that CD11c+ macrophages in DRG have an opposite role to CD11c+ microglia in the spinal cord. Please discuss this result.</p></disp-quote><p>We apologize for the confusion. The aim of the experiments in Figure 4 was to examine the contribution of CD11c+ cells in the DRG to the pain-alleviating effect of intrathecal IL-4. For this aim, we depleted CD11c+ cells in the DRG (but not in the SDH) by intraperitoneal injection of diphtheria toxin (DTX) immediately after the behavioral measurements performed on day 17 (Fig. 4A, B). On day 18, the paw withdrawal threshold of DTX-treated mice was almost similar to that of PBS-treated mice, indicating that the depletion of CD11c+ cells in the DRG does not affect the pain-alleviating effect of IL-4. These data are in stark contrast to those obtained from mice with depletion of CD11c+ cells in the SDH by intrathecal DTX (the depletion canceled the IL-4's effect) (Figure 2A). Thus, it is conceivable that CD11c+ cells in the DRG are not involved in the IL-4-induced alleviating effect on neuropathic pain. Because the confusion might be related to the statement in this paragraph of the initial version, we thus modified our statements to make this point more clearly (line 133â139).</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Recommendations for the authors):</bold></p><p>A discussion addressing how these results fit into existing research on microglial function in pain would enhance the study's impact.</p></disp-quote><p>A brief summary of existing research on microglial function in neuropathic pain has been included at the beginning of the Discussion section (line 188â196).</p><disp-quote content-type="editor-comment"><p>It would be helpful for the authors to elaborate on the implications of their findings within the larger landscape of immune regulation in neuropathic pain.</p></disp-quote><p>Our present findings showed an ability of IL-4, known as a T-cell-derived factor, to increase CD11c+ microglia and to control neuropathic pain. Furthermore, recent studies have also indicated that immune cells such as CD8+ T cells infiltrating into the spinal cord (Neuron 113: 896-911.e9, 2025), and regulatory T cells (eLife 10: e69056, 2021; Science 388: 96â104, 2025) and MRC1+ macrophages in the spinal meninges (Neuron 109: 1274â1282, 2021) have important roles in regulating microglial states and neuropathic pain. Thus, these findings provide new insights into the mechanisms of the neuro-immune interactions that regulate neuropathic pain. In revising the manuscript, we have added above statement in the Discussion section (line 254â260).</p><disp-quote content-type="editor-comment"><p>Furthermore, a discussion on how these findings could inform the development of targeted therapies that modulate microglial populations in a controlled, disease-specific manner would be valuable. Exploring how these insights could lead to novel treatment strategies for neuropathic pain could provide important future directions for the research and broader clinical applications.</p></disp-quote><p>We appreciate the reviewer's valuable suggestion. Our current data, demonstrating that IL-4 increases CD11c+ microglia without affecting the total number of microglia, could open a new avenue for developing strategies to modulate microglial subpopulations through molecular targeting, which may lead to new analgesics. However, given IL-4's association with allergic responses, targeting microglia-selective molecules involved in shifting microglia toward the CD11c+ stateâsuch as intracellular signaling molecules downstream of IL-4 receptorsâmay offer a more selective and safer therapeutic approach. Moreover, since CD11c+ microglia have been implicated in other CNS diseases [e.g., Alzheimer disease (Cell 169: 1276â1290, 2017), amyotrophic lateral sclerosis (Nat Neurosci 25: 26â38, 2022), and multiple sclerosis (Front Cell Neurosci 12: 523, 2019)], further investigations into the mechanisms driving CD11c+ microglia induction could provide insights into novel therapeutic strategies not only for neuropathic pain but also for other CNS diseases. In revising the manuscript, we have added above statement in the Discussion section (line 260â271).</p></body></sub-article></article>